<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIUMEQ- dolutegravir sodium, abacavir sulfate and lamivudineÂ tablet, film coatedÂ </strong><br>ViiV Healthcare Company<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TRIUMEQ safely and effectively. See full prescribing information for TRIUMEQ.<br>TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets for oral use<br>Initial U.S. Approval: 2014</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred with abacavir-containing products. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Patients who carry the HLA-B*5701 allele are at a higher risk of experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">TRIUMEQ is contraindicated in patients with a prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir and in HLA-B*5701-positive patients. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Discontinue TRIUMEQ as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. Regardless of HLA-B*5701 status, permanently discontinue TRIUMEQ if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to TRIUMEQ, NEVER restart TRIUMEQ or any other abacavir-containing product. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (<a href="#ID_e5744bc5-39b1-4a6b-b5e0-842372f65759">5.4</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of TRIUMEQ. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (<a href="#ID_d4b40e43-91db-4c81-98ba-f9097a2498a1">5.5</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="83%">
<col width="17%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><p class="Highlighta">Boxed Warning  </p></td>
<td align="right" valign="top"><p class="Highlighta">09/2015 </p></td>
</tr>
<tr>
<td valign="top"><p class="Highlighta">Dosage and Administration, Dosage Recommendation with Certain Concomitant Medications (<a href="#ID_2cb1439a-180f-45e5-8032-e0c54962b5c3">2.3</a>) </p></td>
<td align="right" valign="top"><dl>
<dt>Â </dt>
<dd>08/2015</dd>
</dl></td>
</tr>
<tr>
<td valign="top"><p class="Highlighta">Dosage and Administration, Not Recommended Due to Lack of Dosage Adjustment (<a href="#ID_e80da7b4-e611-48ce-87d0-1da1973a3053">2.4</a>) </p></td>
<td align="right" valign="top"><dl>
<dt>Â </dt>
<dd>09/2015</dd>
</dl></td>
</tr>
<tr>
<td valign="top"><p class="Highlighta">Contraindications (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>) </p></td>
<td align="right" valign="top"><p class="Highlighta">09/2015 </p></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>) </p></td>
<td align="right" valign="top"><dl>
<dt>Â </dt>
<dd>09/2015</dd>
</dl></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred with abacavir-containing products. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Patients who carry the HLA-B*5701 allele are at a higher risk of experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">TRIUMEQ is contraindicated in patients with a prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir and in HLA-B*5701-positive patients. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Discontinue TRIUMEQ as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. Regardless of HLA-B*5701 status, permanently discontinue TRIUMEQ if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to TRIUMEQ, NEVER restart TRIUMEQ or any other abacavir-containing product. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (<a href="#ID_e5744bc5-39b1-4a6b-b5e0-842372f65759">5.4</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</span></span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of TRIUMEQ. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (<a href="#ID_d4b40e43-91db-4c81-98ba-f9097a2498a1">5.5</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">TRIUMEQ, a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) is indicated for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#ID_35540a6d-2636-493f-8950-8f9bbe91390a">1</a>) </p>
<table width="100%">
<col width="98%">
<col width="2%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top">
<p class="Highlighta"><span class="Underline">Limitations of Use:</span> </p>
<dl>
<dt>â€¢</dt>
<dd>TRIUMEQ alone is not recommended for use in patients with current or past history of resistance to any components of TRIUMEQ. (<a href="#ID_0a8d29f6-1841-4f83-91ba-cf80028be6e1">12.4</a>)</dd>
</dl>
</td>
<td valign="top"></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>â€¢</dt>
<dd>TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in TRIUMEQ is insufficient in these subpopulations. See the dolutegravir prescribing information. (<a href="#ID_35540a6d-2636-493f-8950-8f9bbe91390a">1</a>)</dd>
</dl></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Before initiating TRIUMEQ, screen for the HLAâ€‘B*5701 allele because TRIUMEQ contains abacavir. (<a href="#ID_fe0902b6-0d6e-4c30-8e32-33231fd16c6b">2.1</a>)<span class="Italics">.</span>
</dd>
<dt>â€¢</dt>
<dd>Adults: One tablet daily. May be taken with or without food. (<a href="#ID_667cde5e-9ff6-4f12-96c3-de1657e6f3d2">2.2</a>)</dd>
<dt>â€¢</dt>
<dd>If dosing with certain UGT1A or CYP3A inducers, then the recommended dolutegravir dosage regimen is 50 mg twice daily. An additional 50-mg dose of dolutegravir, separated by 12 hours from TRIUMEQ, should be taken. (<a href="#ID_2cb1439a-180f-45e5-8032-e0c54962b5c3">2.3</a>) </dd>
<dt>â€¢</dt>
<dd>Because TRIUMEQ is a fixed-dose tablet and cannot be dose adjusted, TRIUMEQ is not recommended in patients requiring dosage adjustment or patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#ID_e80da7b4-e611-48ce-87d0-1da1973a3053">2.4</a>, <a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 600Â mg of abacavir, 50Â mg of dolutegravir, and 300Â mg of lamivudine. (<a href="#ID_f3828cf2-de25-4065-a22b-96428ae2db4e">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Presence of HLA-B*5701 allele. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>)</dd>
<dt>â€¢</dt>
<dd>Prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, dolutegravir, or lamivudine. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>)</dd>
<dt>â€¢</dt>
<dd>Coadministration with dofetilide. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>)</dd>
<dt>â€¢</dt>
<dd>Moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>, <a href="#ID_b01dc070-5222-4604-99f6-3b06156dbca5">8.7</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C may be at increased risk for worsening or development of transaminase elevations with use of TRIUMEQ. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TRIUMEQ is recommended in patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C. (<a href="#ID_251c9e9b-8d9c-402e-933e-51f09083156b">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>Hepatic decompensation, some fatal, has occurred in HIV-1/HCV coâ€‘infected patients receiving combination antiretroviral therapy and interferon alfa with or without ribavirin. Discontinue TRIUMEQ as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (<a href="#ID_e5744bc5-39b1-4a6b-b5e0-842372f65759">5.4</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy. (<a href="#ID_d4b40e43-91db-4c81-98ba-f9097a2498a1">5.5</a>, <a href="#ID_36d798f4-0766-4a52-b4d8-ebb71f42c23a">5.6</a>) </dd>
<dt>â€¢</dt>
<dd>Administration of TRIUMEQ is not recommended in patients receiving other products containing abacavir or lamivudine. (<a href="#ID_091c6428-c82b-4a7c-be84-bc2170d0f4cb">5.8</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions of at least moderate intensity and incidence at least 2% (in those receiving TRIUMEQ) were <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. (<a href="#ID_ca7e5dff-7d49-424c-bd0f-78d63ecf4406">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Coadministration of TRIUMEQ with other drugs can alter the concentration of other drugs and other drugs may alter the concentrations of TRIUMEQ. The potential drug-drug interactions must be considered prior to and during therapy. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>, <a href="#ID_98eecaff-c9ce-4839-86ae-193bbefabecd">7</a>, <a href="#ID_0cce10ff-903c-47dd-8138-7f5bea219743">12.3</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Nursing mothers: Breastfeeding is not recommended due to the potential for HIV transmission. (<a href="#ID_91fa7bf0-9308-48bc-ae15-cb4b8f9ab630">8.3</a>)</dd>
<dt>â€¢</dt>
<dd>TRIUMEQ is not recommended in patients with creatinine clearance less than 50 mL per min. (<a href="#ID_cdd8f215-e128-4a4d-8dee-fdf3dfd65aed">8.6</a>)</dd>
<dt>â€¢</dt>
<dd>If a dose reduction of abacavir, a component of TRIUMEQ, is required for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, then the individual components should be used. (<a href="#ID_b01dc070-5222-4604-99f6-3b06156dbca5">8.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Screening for HLA-B*5701 Allele prior to Starting TRIUMEQ</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dosage</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage Recommendation with Certain Concomitant Medications</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Not Recommended Due to Lack of Dosage Adjustment </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATION</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use with Interferon- and Ribavirin-based Regimens</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Fat Redistribution</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Related Products that are Not Recommended</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effect of Other Agents on the Pharmacokinetics of Dolutegravir</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Established and Other Potentially Significant Drug Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with Impaired Hepatic Function</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Subjects</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_081a78b4-d7a3-4691-b4c4-f1d554a6f8e2"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span>, and EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, with multiple organ involvement, have occurred with abacavir, a component of TRIUMEQ<span class="Sup">Â®</span> (abacavir, dolutegravir, and lamivudine). Patients who carry the HLAâ€‘B*5701 allele are at a higher risk of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir; although, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred in patients who do not carry the HLAâ€‘B*5701 allele <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">TRIUMEQ is contraindicated in patients with a prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir and in HLAâ€‘B*5701-positive patients <span class="Italics">[see Contraindications (4), Warnings and Precautions (5.1)]</span>. All patients should be screened for the HLAâ€‘B*5701 allele prior to initiating therapy with TRIUMEQ or reinitiation of therapy with TRIUMEQ, unless patients have a previously documented HLAâ€‘B*5701 allele assessment. Discontinue TRIUMEQ immediately if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible <span class="Italics">[see Contraindications (4), Warnings and Precautions (5.1)]</span>. </span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to TRIUMEQ, NEVER restart TRIUMEQ or any other abacavirâ€‘containing product because more severe symptoms, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</span></span></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir, lamivudine, and other antiretrovirals. Discontinue TRIUMEQ if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</span></p>
<p><span class="Bold"><span class="Underline">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</span></span></p>
<p><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co</span>â€‘<span class="Bold">infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of TRIUMEQ. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue TRIUMEQ and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti</span>â€‘<span class="Bold"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_35540a6d-2636-493f-8950-8f9bbe91390a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">TRIUMEQ is indicated for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Underline">Limitations of Use:</span></p>
<dl>
<dt>â€¢</dt>
<dd>TRIUMEQ alone is not recommended for use in patients with current or past history of resistance to any components of TRIUMEQ <span class="Italics">[see Microbiology (12.4)].</span>
</dd>
<dt>â€¢</dt>
<dd>TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in TRIUMEQ is insufficient in these subpopulations. See full prescribing information for dolutegravir.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_8f2c467c-aa24-4575-93c2-a09c744e319c"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fe0902b6-0d6e-4c30-8e32-33231fd16c6b"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Screening for HLA-B*5701 Allele prior to Starting TRIUMEQ</h2>
<p class="First">Screen for the HLAâ€‘B*5701 allele prior to initiating therapy with TRIUMEQ <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_667cde5e-9ff6-4f12-96c3-de1657e6f3d2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dosage</h2>
<p class="First">TRIUMEQ is a fixed-dose combination product containing 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine. The recommended dosage regimen of TRIUMEQ in adults is one tablet once daily orally with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2cb1439a-180f-45e5-8032-e0c54962b5c3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage Recommendation with Certain Concomitant Medications</h2>
<p class="First">The dolutegravir dose (50 mg) in TRIUMEQ is insufficient when coadministered with medications listed in Table 1 that may decrease dolutegravir concentrations; the following dolutegravir dosage regimen is recommended.</p>
<p><span class="Bold">Table 1. Dosing Recommendations for TRIUMEQ with Coadministered Medications</span></p>
<table width="100%">
<col width="39%">
<col width="61%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Dosing Recommendation</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First" style="border-left:1px solid;"><span class="XmChange">Efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">The recommended dolutegravir dosage regimen is 50 mg twice daily. An additional dolutegravir 50-mg tablet, separated by 12 hours from TRIUMEQ, should be taken.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e80da7b4-e611-48ce-87d0-1da1973a3053"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Not Recommended Due to Lack of Dosage Adjustment </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Because TRIUMEQ is a fixed-dose tablet and cannot be dose adjusted, TRIUMEQ is not recommended in:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="XmChange">patients with creatinine clearance less than 50 mL per minute <span class="Italics">[see Use in Specific Populations (8.6)].</span></span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. TRIUMEQ is contraindicated in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span><span class="Italics"> [see Contraindications (4), Use in Specific Populations (8.7)]</span>.</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_f3828cf2-de25-4065-a22b-96428ae2db4e"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TRIUMEQ tablets are purple, biconvex, oval, and debossed with â€œ572 TrÄ±â€? on one side. Each film-coated tablet contains abacavir sulfate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg of dolutegravir, and 300 mg of lamivudine <span class="Italics">[see Description (11)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATION</h1>
<p class="First">TRIUMEQ is contraindicated in patients:</p>
<dl>
<dt>â€¢</dt>
<dd>who have the HLA-B*5701 allele <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="XmChange">with prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, dolutegravir <span class="Italics">[see Warnings and Precautions (5.1)]</span>, or lamivudine.</span></dd>
<dt>â€¢</dt>
<dd>r<span class="XmChange">eceiving dofetilide, due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events with concomitant use of dolutegravir <span class="Italics">[see Drug Interactions (7)]</span>.</span>
</dd>
<dt>â€¢</dt>
<dd>with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Use in Specific Populations (8.7)].</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_70c10965-2048-4a08-ac8a-8f6e912c89e2"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_27bad223-81e5-4a9c-b653-ec5631b83e77"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been reported with the use of abacavir or dolutegravir, components of TRIUMEQ.</p>
<p><span class="Underline">Abacavir</span></p>
<p>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred with abacavir containing regimens. See full prescribing information for ZIAGEN<span class="Sup">Â®</span> (abacavir). </p>
<p style="border-left:1px solid;"><span class="XmChange">Abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have included multi-organ failure and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and typically occurred within the first 6Â weeks of treatment with abacavir (median time to onset was 9Â days); although abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred any time during treatment <span class="Italics">[see Adverse Reactions (6.1)]</span>. Patients who carry the HLAâ€‘B*5701 allele are at a higher risk of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>; although, patients who do not carry the HLAâ€‘B*5701 allele have developed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir was reported in approximately 206 (8%) of 2,670 patients in 9 clinical trials with abacavir-containing products where HLAâ€‘B*5701 screening was not performed. The incidence of suspected abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in clinical trials was 1% when subjects carrying the HLA-B*5701 allele were excluded. In any patient treated with abacavir, the clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> must remain the basis of clinical decision making. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Due to the potential for severe, serious, and possibly fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> with abacavir:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="XmChange">All patients should be screened for the HLAâ€‘B*5701 allele prior to initiating therapy with TRIUMEQ or reinitiation of therapy with TRIUMEQ, unless patients have a previously documented HLAâ€‘B*5701 allele assessment. </span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">TRIUMEQ is contraindicated in patients with a prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir and in HLAâ€‘B*5701â€‘positive patients. </span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">Before starting TRIUMEQ, review medical history for prior exposure to any abacavir-containing product. NEVER restart TRIUMEQ or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, regardless of HLAâ€‘B*5701 status.</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">To reduce the risk of a lifeâ€‘threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, regardless of HLAâ€‘B*5701 status, discontinue TRIUMEQ immediately if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected, even when other diagnoses are possible (e.g., acute onset respiratory diseases such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>; <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>; or reactions to other medications). Clinical status, including liver chemistries, should be monitored and appropriate therapy initiated.</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">If a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> cannot be ruled out, do not restart TRIUMEQ or any other abacavir-containing products because more severe symptoms, which may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, can occur within hours.</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">Clinically, it is not possible to determine whether a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> with TRIUMEQ would be caused by abacavir or dolutegravir. Therefore, never restart TRIUMEQ or any other abacavir- or dolutegravir-containing product in patients who have stopped therapy with TRIUMEQ due to a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">If a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is ruled out, patients may restart TRIUMEQ. Rarely, patients who have stopped abacavir for reasons other than symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have also experienced life-threatening reactions within hours of reinitiating abacavir therapy. Therefore, reintroduction of TRIUMEQ, or any other abacavir-containing product, reintroduction of TRIUMEQ or any other abacavir-containing product is recommended only if medical care can be readily accessed.</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">A Medication Guide and Warning Card that provide information about recognition of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should be dispensed with each new prescription and refill.</span></dd>
</dl>
<p><span class="Underline">Dolutegravir</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been reported and were characterized by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and sometimes organ dysfunction, including <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. The events were reported in less than 1% of subjects receiving TIVICAY<span class="Sup">Â®</span> in Phase 3 clinical trials. Discontinue TRIUMEQ and other suspect agents immediately if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> develop (including, but not limited to, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of the skin, oral <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or lesions, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>). Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated. Delay in stopping treatment with TRIUMEQ or other suspect agents after the onset of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> may result in a life-threatening reaction.</p>
<p>Clinically, it is not possible to determine whether a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> with TRIUMEQ would be caused by abacavir or dolutegravir. Therefore, never restart TRIUMEQ or any other abacavir- or dolutegravir-containing product in patients who have stopped therapy with TRIUMEQ due to a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_14f9ed40-f510-4437-8a16-3e528a629326"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. See full prescribing information for ZIAGEN (abacavir) and EPIVIR<span class="Sup">Â®</span> (lamivudine). Treatment with TRIUMEQ should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_251c9e9b-8d9c-402e-933e-51f09083156b"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></h2>
<p class="First"><span class="Underline">Effects on Serum Liver Biochemistries</span></p>
<p>Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C may be at increased risk for worsening or development of transaminase elevations with use of TRIUMEQ <span class="Italics">[see Adverse Reactions (6.1)]</span>. See full prescribing information for TIVICAY<span class="Sup">Â®</span> (dolutegravir). In some cases the elevations in transaminases were consistent with <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span> or <span class="product-label-link" type="condition" conceptid="4281232" conceptname="Type B viral hepatitis">hepatitis B reactivation</span> particularly in the setting where anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> therapy was withdrawn. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TRIUMEQ are recommended in patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C.</p>
<p><span class="Underline">Posttreatment Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></span></p>
<p>Clinical and laboratory evidence of exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have occurred after discontinuation of lamivudine. See full prescribing information for EPIVIR (lamivudine). Patients should be closely monitored with both clinical and laboratory followâ€‘up for at least several months after stopping treatment.</p>
<p><span class="Underline">Emergence of Lamivudineâ€‘resistant HBV</span></p>
<p>Safety and efficacy of lamivudine have not been established for treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B in subjects dually infected with HIV-1 and HBV. Emergence of hepatitisÂ B virus variants associated with resistance to lamivudine has been reported in HIVâ€‘1â€‘infected subjects who have received lamivudineâ€‘containing antiretroviral regimens in the presence of concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with hepatitisÂ B virus. See full prescribing information for EPIVIR-HBV<span class="Sup">Â®</span> (lamivudine).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e5744bc5-39b1-4a6b-b5e0-842372f65759"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use with Interferon- and Ribavirin-based Regimens</h2>
<p class="First">Patients receiving interferon alfa with or without ribavirin and TRIUMEQ should be closely monitored for treatmentâ€‘associated toxicities, especially hepatic decompensation. See full prescribing information for EPIVIR (lamivudine). Discontinuation of TRIUMEQ should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Childâ€‘Pugh greater than 6) (see full prescribing information for interferon and ribavirin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d4b40e43-91db-4c81-98ba-f9097a2498a1"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including TRIUMEQ. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment. </p>
<p><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_36d798f4-0766-4a52-b4d8-ebb71f42c23a"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8633684e-17a1-4954-bea2-34c6f2534462"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">In a published prospective, observational, epidemiological trial designed to investigate the rate of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) in patients on combination antiretroviral therapy, the use of abacavir within the previous 6Â months was correlated with an increased risk of MI. In a sponsorâ€‘conducted pooled analysis of clinical trials, no excess risk of MI was observed in abacavirâ€‘treated subjects as compared with control subjects. In totality, the available data from the observational cohort and from clinical trials are inconclusive.</p>
<p>As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, smoking).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_091c6428-c82b-4a7c-be84-bc2170d0f4cb"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Related Products that are Not Recommended</h2>
<p class="First">TRIUMEQ contains fixed doses of an INSTI (dolutegravir) and 2 nucleoside analogue reverse transcriptase inhibitors (abacavir and lamivudine); concomitant administration of TRIUMEQ with other products containing abacavir or lamivudine is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_ced153d2-1d08-470b-9c9b-b084c4984fae"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.2)]</span>.</dd>
<dt>â€¢</dt>
<dd>Effects on serum liver biochemistries in patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</dd>
<dt>â€¢</dt>
<dd>Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.3)]</span>.</dd>
<dt>â€¢</dt>
<dd>Hepatic decompensation in patients co-infected with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</dd>
<dt>â€¢</dt>
<dd>Fat redistribution <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> <span class="Italics">[see Warnings and Precautions (5.7)]</span>.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ca7e5dff-7d49-424c-bd0f-78d63ecf4406"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p><span class="Underline">Serious and Fatal Abacavir-associated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>In clinical trials, serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred with abacavir, a component of TRIUMEQ <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)].</span> These reactions have been characterized by 2 or more of the following signs or symptoms: (1) <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; (2) <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; (3) <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>); (4) constitutional symptoms (including generalized <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or achiness); (5) respiratory symptoms (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>). Almost all abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> as part of the syndrome.</p>
<p>Other signs and symptoms have included <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, myolysis, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in association with these <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Physical findings have included <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, mucous membrane lesions (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcerations</span>), and maculopapular or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticarial rash</span> (although some patients had other types of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> and others did not have a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>). There were reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Laboratory abnormalities included elevated liver chemistries, elevated creatine phosphokinase, elevated creatinine, and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> and abnormal chest xâ€‘ray findings (predominantly infiltrates, which were localized).</p>
<p><span class="Underline">Serious Dolutegravir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>In clinical trials, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred with dolutegravir, a component of TRIUMEQ <span class="Italics">[see Warnings and Precautions (5.1)].</span> These <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been characterized by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and sometimes organ dysfunction, including <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. </p>
<p><span class="Underline">Additional Treatment-emergent Adverse Drug Reactions (ADRs) with Use of TRIUMEQ</span></p>
<p>The safety assessment of TRIUMEQ is primarily based on the analyses of data from a randomized, international, multicenter, double-blind, active-controlled trial, SINGLE (ING114467) and supported by data in treatment-experienced, INSTI-naÃ¯ve subjects from SAILING (ING111762) and by data from other treatment-naÃ¯ve trials. See full prescribing information for TIVICAY.</p>
<p><span class="Italics">Treatment-naÃ¯ve Subjects:</span> In SINGLE, 833Â adult subjects were randomized and received at least one dose of either dolutegravir (TIVICAY) 50Â mg with fixed-dose abacavir and lamivudine (EPZICOM<span class="Sup">Â®</span>) once daily (nÂ =Â 414) or fixed-dose efavirenz/emtricitabine/tenofovir (ATRIPLA<span class="Sup">Â®</span>) once daily (nÂ =Â 419). Through 96 weeks, the rate of adverse events leading to discontinuation was 3% in subjects receiving TIVICAY + EPZICOM and 12% in subjects receiving ATRIPLA once daily.</p>
<p>Treatment-emergent ADRs of moderate to severe intensity observed in at least 2% of subjects in either treatment arm of SINGLE are provided in Table 2.</p>
<p><span class="Bold">Table 2. Treatment</span>-<span class="Bold">emergent Adverse Drug Reactions of at Least Moderate Intensity (Grades 2 to 4) and at Least 2% Frequency in Treatment</span>-<span class="Bold">naÃ¯ve Subjects in SINGLE (Week 96 Analysis)</span></p>
<table width="100%">
<col width="45%">
<col width="27%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY + EPZICOM</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 414)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">ATRIPLA</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 419)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Psychiatric </span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Nervous System</span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Gastrointestinal </span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">General Disorders </span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue </span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Ear and Labyrinth </span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Includes pooled terms: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, and <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span>.</p>
<p><span class="Italics">Treatment-experienced Subjects: </span>SAILING is an international, double-blind trial in INSTI-naÃ¯ve, antiretroviral treatment-experienced adult subjects. Subjects were randomized and received either TIVICAY 50Â mg once daily or raltegravir 400Â mg twice daily with investigator-selected background regimen consisting of up to 2Â agents, including at least one fully active agent. At 48 weeks, the rate of adverse events leading to discontinuation was consistent with that seen in the overall treatment-naÃ¯ve patient population. See full prescribing information for TIVICAY.</p>
<p>The ADRs observed in the subset of subjects who received TIVICAYÂ +Â EPZICOM were generally consistent with those seen in the overall treatment-naÃ¯ve patient population.</p>
<p><span class="Underline">Less Common Adverse Reactions Observed in Clinical Trials</span></p>
<p>The following adverse reactions occurred in less than 2% of treatment-naÃ¯ve or treatment-experienced subjects in any one trial. These events have been included because of their seriousness and/or assessment of potential causal relationship.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Italics">General Disorders:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>.</p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>.</p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>.</p>
<p><span class="Italics">Nervous:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>.</p>
<p><span class="Italics">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span>, attempt, behavior, or completion. These events were observed primarily in subjects with a pre-existing history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other psychiatric illness. <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">Nightmare</span> and <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>.</p>
<p><span class="Italics">Renal and Urinary Disorders: </span><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>.</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>.</p>
<p><span class="Underline">Laboratory Abnormalities</span></p>
<p><span class="Italics">Treatment-naÃ¯ve Subjects:</span> Selected laboratory abnormalities (Grades 2 to 4) with a worsening grade from baseline and representing the worst-grade toxicity in at least 2% of subjects in SINGLE are presented in Table 3. The mean change from baseline observed for selected lipid values is presented in Table 4.</p>
<p><span class="Bold">Table 3. Selected Laboratory Abnormalities (Grades 2 to 4) in Treatment-naÃ¯ve Subjects in SINGLE (Week 96 Analysis)</span></p>
<table width="100%">
<col width="43%">
<col width="29%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Laboratory Abnormality</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY + EPZICOM</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 414)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">ATRIPLA</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 419)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">ALT</p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  Grade 2 (&gt;2.5-5.0 x ULN)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Grade 3 to 4 (&gt;5.0 x ULN)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">AST</p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  Grade 2 (&gt;2.5-5.0 x ULN)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Grade 3 to 4 (&gt;5.0 x ULN)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Creatine kinase</p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  Grade 2 (6.0-9.9 x ULN)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">4%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Grade 3 to 4 (â‰¥10.0 x ULN)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  Grade 2 (126-250 mg/dL)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">7%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Grade 3 (&gt;250 mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Lipase</p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  Grade 2 (&gt;1.5-3.0 x ULN)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">9%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Grade 3 to 4 (&gt;3.0 ULN)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Total <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  Grade 2 (0.75-0.99 x 10<span class="Sup">9</span>)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Grade 3 to 4 (&lt;0.75 x 10<span class="Sup">9</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
</tbody>
</table>
<p>ULN = Upper limit of normal.</p>
<p><span class="Bold">Table 4. Mean Change from Baseline in Fasted Lipid Values in Treatment-naÃ¯ve Subjects in SINGLE (Week 96 Analysis<span class="Sup">a</span>)</span></p>
<table width="100%">
<col width="40%">
<col width="30%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Lipid</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY + EPZICOM</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 414)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">ATRIPLA</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 419)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">23.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Triglycerides (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17.4</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Subjects on lipid-lowering agents at baseline were excluded from these analyses (TIVICAY nÂ =Â 30 and ATRIPLA nÂ =Â 27). Fifty-five subjects initiated a lipid-lowering agent post-baseline; their last fasted on-treatment values (prior to starting the agent) were used regardless if they discontinued the agent (SINGLE: TIVICAY nÂ =Â 25 and ATRIPLA: nÂ =Â 30).</p>
<p><span class="Italics">Treatment-experienced Subjects: </span>Laboratory abnormalities observed in SAILING were generally similar compared with observations seen in the treatment-naÃ¯ve trials.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></p>
<p>In SINGLE, the pivotal Phase 3 trial, subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were permitted to enroll provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal; subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were excluded. Overall, the safety profile in subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was similar to that observed in subjects without <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, although the rates of AST and ALT abnormalities were higher in the subgroup with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> for both treatment groups. Grades 2 to 4 ALT abnormalities in <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C co-infected compared with HIV mono-infected subjects receiving TRIUMEQ were observed in 15%Â andÂ 2% (vs. 24% and 4% of subjects treated with ATRIPLA), respectively <span class="Italics">[see Warnings and Precautions (5.3)]</span>. See also full prescribing information for TIVICAY.</p>
<p><span class="Italics">Changes in Serum Creatinine:</span> Dolutegravir has been shown to increase serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function <span class="Italics">[see Clinical Pharmacology (12.2)]</span>. Increases in serum creatinine occurred within the first 4 weeks of treatment and remained stable through 24 to 96 weeks. In SINGLE, a mean change from baseline of 0.14Â mg per dL (range: -0.32Â mg per dL to 0.59Â mg per dL) was observed after 96Â weeks of treatment. Creatinine increases were similar in treatment-experienced subjects.</p>
<p><span class="Underline">Abacavir and Lamivudine</span></p>
<p>Laboratory abnormalities observed in clinical trials of ZIAGEN (in combination with other antiretroviral treatment) were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, liver function test abnormalities, and elevations of CPK, blood glucose, and triglycerides. Additional laboratory abnormalities observed in clinical trials of EPIVIR (in combination with other antiretroviral treatment) were <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and elevated levels of bilirubin, amylase, and lipase.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d27bf0a6-10b6-4311-8cb1-df43afae66e0"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postmarketing use. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Underline">Abacavir and/or Lamivudine:</span></p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>.</p>
<p><span class="Italics">General:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.</p>
<p><span class="Italics">Blood and Lymphatic Systems:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (including pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> progressing on therapy), <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Sensitization reactions (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> <span class="Italics">[see Warnings and Precautions (5.1), Adverse Reactions (6.1)]</span>.</p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> Hyperlactemia.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>, CPK elevation, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Italics">Nervous:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="Italics">Respiratory:</span> Abnormal breath sounds/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>. </p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Suspected <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) have been reported in patients receiving abacavir primarily in combination with medications known to be associated with SJS and TEN, respectively. Because of the overlap of clinical signs and symptoms between <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir and SJS and TEN, and the possibility of multiple drug sensitivities in some patients, abacavir should be discontinued and not restarted in such cases <span class="Italics">[see Adverse Reactions (6.1)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_98eecaff-c9ce-4839-86ae-193bbefabecd"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1144cd21-866d-4f0a-b6d2-36c4d18535eb"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents</h2>
<p class="First">In vitro, dolutegravir inhibited the renal organic cation transporters, OCT2 (IC<span class="Sub">50</span> = 1.93 microM) and multidrug and toxin extrusion transporter (MATE) 1 (IC<span class="Sub">50</span> = 6.34 microM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin) <span class="Italics">[see Contraindications (4), Drug Interactions (7.3)].</span></p>
<p>In vitro, dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 (IC<span class="Sub">50</span> = 2.12 microM) and OAT3 (IC<span class="Sub">50</span> = 1.97 microM). However, in vivo, dolutegravir did not alter the plasma concentrations of tenofovir or para-amino hippurate, substrates of OAT1 and OAT3.</p>
<p>In vitro, dolutegravir did not inhibit (IC<span class="Sub">50</span> greater than 50 microM) the following: cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1, UGT2B7, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, or multidrug resistance protein (MRP)2, or MRP4. In vitro, dolutegravir did not induce CYP1A2, CYP2B6, CYP3A4. Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.</p>
<p>In drug interaction trials, dolutegravir did not have a clinically relevant effect on the pharmacokinetics of the following drugs: tenofovir, methadone, midazolam, rilpivirine, and oral contraceptives containing norgestimate and ethinyl estradiol. Using cross-study comparisons to historical pharmacokinetic data for each interacting drug, dolutegravir did not appear to affect the pharmacokinetics of the following drugs: atazanavir, darunavir, efavirenz, etravirine, fosamprenavir, lopinavir, ritonavir, and boceprevir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8e385057-d5d7-41a8-abf7-9359e97b0910"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effect of Other Agents on the Pharmacokinetics of Dolutegravir</h2>
<p class="First">Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A. Dolutegravir is also a substrate of UGT1A3, UGT1A9, BCRP, and P-gp in vitro. Drugs that induce those enzymes and transporters may decrease dolutegravir plasma concentrations and reduce the therapeutic effect of dolutegravir.</p>
<p>Coadministration of dolutegravir and other drugs that inhibit these enzymes may increase dolutegravir plasma concentrations.</p>
<p>Etravirine significantly reduced plasma concentrations of dolutegravir, but the effect of etravirine was mitigated by coadministration of lopinavir/ritonavir or darunavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir (Table 5) <span class="Italics">[see Drug Interactions (7.3), Clinical Pharmacology (12.3)]</span>.</p>
<p>In vitro, dolutegravir was not a substrate of OATP1B1, or OATP1B3.</p>
<p>Darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, tenofovir, boceprevir, prednisone, rifabutin, and omeprazole had no clinically significant effect on the pharmacokinetics of dolutegravir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4d2229de-0047-499f-8787-6bd8f587f67e"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Established and Other Potentially Significant Drug Interactions</h2>
<p class="First">There were no drug-drug interaction trials conducted with the abacavir, dolutegravir, and lamivudine fixed-dose combination tablets.</p>
<p>Information regarding potential drug interactions with dolutegravir (Table 5) and abacavir are provided below. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy. <span class="Italics">[See Clinical Pharmacology (12.3).]</span></p>
<p><span class="Bold">Table 5. Established and Other Potentially Significant Drug Interactions for Dolutegravir: Alterations in Dose May Be Recommended Based on Drug Interaction Trials or Predicted Interactions</span></p>
<table width="100%">
<col width="30%">
<col width="16%">
<col width="54%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Concomitant Drug Class:</span><br><span class="Bold">Drug Name</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Effect on Concentration</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Clinical Comment</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold"><span class="Italics">HIV-1 Antiviral Agents</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
<p>Etravirine<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Use of TRIUMEQ with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
<p>Efavirenz<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Adjust dolutegravir dose to 50Â mg twice daily. An additional 50-mg dose of dolutegravir should be taken, separated by 12Â hours from TRIUMEQ.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
<p>Nevirapine</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Avoid coadministration with TRIUMEQ because there are insufficient data to make dosing recommendations.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Protease inhibitor:</span></p>
<p>Fosamprenavir/ritonavir<span class="Sup">a</span><br>Tipranavir/ritonavir<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Adjust dolutegravir dose to 50Â mg twice daily. An additional dolutegravir 50-mg dose should be taken, separated by 12 hours from TRIUMEQ.</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold"><span class="Italics">Other Agents</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Carbamazepine<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Adjust dolutegravir dose to 50Â mg twice daily. An additional dolutegravir 50-mg dose should be taken, separated by 12 hours from TRIUMEQ.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oxcarbazepine<br>Phenytoin<br>Phenobarbital<br>St. Johnâ€™s wort (<span class="Italics">Hypericum perforatum</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Avoid coadministration with TRIUMEQ because there are insufficient data to make dosing recommendations.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Medications containing polyvalent cations</span><br><span class="Bold">(e.g., Mg or Al):</span></p>
<p>Cation-containing antacids<span class="Sup">a</span> or laxatives<br>Sucralfate<br>Buffered medications</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Administer TRIUMEQ 2Â hours before or 6Â hours after taking medications containing polyvalent cations.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Oral calcium and iron supplements, including multivitamins containing calcium or iron<span class="Sup">a</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Administer TRIUMEQ 2Â hours before or 6Â hours after taking supplements containing calcium or iron. Alternatively, TRIUMEQ and supplements containing calcium or iron can be taken together with food.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Metformin<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†‘Metformin</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">With concomitant use, limit the total daily dose of metformin to 1,000Â mg either when starting metformin or TRIUMEQ. When stopping TRIUMEQ, the metformin dose may require an adjustment. Monitoring of blood glucose when initiating concomitant use and after withdrawal of TRIUMEQ is recommended.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Rifampin<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Adjust dolutegravir dose to 50Â mg twice daily. An additional 50-mg dose of dolutegravir should be taken, separated by 12 hours from TRIUMEQ. </p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span><span class="Italics">See Clinical Pharmacology (12.3) Table 8 or Table 9 for magnitude of interaction.</span></p>
<p><span class="Underline">Methadone</span></p>
<p><span class="Italics">Abacavir:</span> In a trial of 11 HIV-1-infected subjects receiving methadone-maintenance therapy with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_e6ce3313-c6a5-42fd-bb1b-6b2f56e05283"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_e50ba56b-d158-4b28-ac99-557d789858a3"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. There are no adequate and wellâ€‘controlled trials in pregnant women. Reproduction studies with the components of TRIUMEQ have been performed in animals (see Dolutegravir, Abacavir, and Lamivudine sections below). Animal reproduction studies are not always predictive of human response. TRIUMEQ should be used during pregnancy only if the potential benefit outweigh the risks.</p>
<p><span class="Underline">Antiretroviral Pregnancy Registry</span></p>
<p>To monitor maternalâ€‘fetal outcomes of pregnant women exposed to TRIUMEQ or other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1â€‘800â€‘258â€‘4263.</p>
<p><span class="Underline">Animal Data</span></p>
<p><span class="Italics">Dolutegravir:</span> Reproduction studies performed in rats and rabbits at doses up to 50 times the human dose of 50Â mg once daily have revealed no evidence of impaired fertility or harm to the fetus due to dolutegravir.</p>
<p>Oral administration of dolutegravir to pregnant rats at doses up to 1,000Â mg per kg daily, approximately 50 times the 50-mg once-daily human clinical exposure based on AUC, from days 6 to 17 of gestation did not elicit maternal toxicity, developmental toxicity, or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p>Oral administration of dolutegravir to pregnant rabbits at doses up to 1,000Â mg per kg daily, approximately 0.74 times the 50-mg once-daily human clinical exposure based on AUC, from days 6 to 18 of gestation did not elicit developmental toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. In rabbits, maternal toxicity (decreased food consumption, scant/no feces/urine, suppressed body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>) was observed at 1,000Â mg per kg.</p>
<p><span class="Italics">Abacavir: </span>Studies in pregnant rats showed that abacavir is transferred to the fetus through the placenta. <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">Fetal malformations</span> (increased incidences of fetal <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span> and skeletal malformations) and developmental toxicity (depressed fetal body weight and reduced crownâ€‘rump length) were observed in rats at a dose which produced 28Â times the human exposure for a dose of 600Â mg based on AUC. Embryonic and fetal toxicities (increased resorptions, decreased fetal body weights) and toxicities to the offspring (increased incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> and lower body weights) occurred at half of the above-mentioned dose in separate fertility studies conducted in rats. In the rabbit, no developmental toxicity and no increases in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> occurred at doses that produced 7Â times the human exposure at the recommended dose based on AUC.</p>
<p><span class="Italics">Lamivudine: </span>Studies in pregnant rats showed that lamivudine is transferred to the fetus through the placenta. Reproduction studies with orally administered lamivudine have been performed in rats and rabbits at doses producing plasma levels up to approximately 32Â times the human exposure for a dose of 300Â mg. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to lamivudine was observed. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at plasma levels up to 32Â times those in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_91fa7bf0-9308-48bc-ae15-cb4b8f9ab630"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The Centers for Disease Control and Prevention recommend that HIVâ€‘1â€‘infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Because of both the potential for HIVâ€‘1 transmission and the potential for serious adverse reactions in nursing infants, instruct <span class="Bold">mothers not to breastfeed.</span></p>
<p><span class="Underline">Dolutegravir</span></p>
<p>Studies in lactating rats and their offspring indicate that dolutegravir was present in rat milk. It is not known whether dolutegravir is excreted in human breast milk.</p>
<p><span class="Underline">Abacavir</span></p>
<p>Abacavir is excreted in the milk of lactating rats.</p>
<p><span class="Underline">Lamivudine</span></p>
<p>Lamivudine is excreted in human breast milk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_605e5dd5-e206-4323-822a-76f89c02e421"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of TRIUMEQ in pediatric patients have not been established <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7b58f8fe-28aa-4529-b46f-2d9c7fa87413"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of abacavir, dolutegravir, or lamivudine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, caution should be exercised in the administration of TRIUMEQ in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see Clinical Pharmacology (12.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cdd8f215-e128-4a4d-8dee-fdf3dfd65aed"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">TRIUMEQ is not recommended for patients with creatinine clearance less than 50Â mL per min because TRIUMEQ is a fixed-dose combination and the dosage of the individual components cannot be adjusted. If a dose reduction of lamivudine, a component of TRIUMEQ, is required for patients with creatinine clearance less than 50Â mL per min, then the individual components should be used <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b01dc070-5222-4604-99f6-3b06156dbca5"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with Impaired Hepatic Function</h2>
<p class="First">TRIUMEQ is a fixed-dose combination and the dosage of the individual components cannot be adjusted. If a dose reduction of abacavir, a component of TRIUMEQ, is required for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score A), then the individual components should be used <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<p>The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate (Child-Pugh Score B) or severe (Child-Pugh Score C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; therefore, TRIUMEQ is contraindicated in these patients <span class="Italics">[see Contraindications (4)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_05741435-c3fa-4c5d-967e-8c177be352a7"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known specific treatment for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with TRIUMEQ. If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, the patient should be monitored and standard supportive treatment applied as required.</p>
<p><span class="Underline">Dolutegravir</span></p>
<p>As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.</p>
<p><span class="Underline">Abacavir</span></p>
<p>It is not known whether abacavir can be removed by peritoneal dialysis or hemodialysis.</p>
<p><span class="Underline">Lamivudine</span></p>
<p>Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> event.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_ee09854e-f417-49a1-9ff6-a01dc162be87"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><span class="Underline">TRIUMEQ</span></p>
<p>TRIUMEQ contains an INSTI (dolutegravir) and 2Â nucleoside analogues (abacavir and lamivudine) with inhibitory activity against HIV.</p>
<p>Each film-coated tablet contains abacavir sulfate equivalent to 600Â mg of abacavir, dolutegravir sodium equivalent to 50Â mg of dolutegravir, and 300Â mg of lamivudine. TRIUMEQ tablets are purple, biconvex, oval, debossed with â€œ572 TrÄ±â€? on one side and contain the inactive ingredients D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate. The tablet film-coating (OPADRY<span class="Sup">Â®</span> II Purple 85F90057) contains the inactive ingredients iron oxide black, iron oxide red, macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium oxide.</p>
<p><span class="Underline">Abacavir Sulfate</span></p>
<p>The chemical name of abacavir sulfate is <span class="Italics">(</span>1<span class="Italics">S,cis)-</span>4-[2-amino-6-(cyclopropylamino)-9<span class="Italics">H</span>-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). It has a molecular formula of (C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">6</span>O)<span class="Sub">2â€¢</span>H<span class="Sub">2</span>SO<span class="Sub">4</span> and a molecular weight of 670.76 g per mol. It has the following structural formula:</p>
<div class="Figure">
<a name="id2743521"></a><img alt="Ziagen chem structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2997739a-aa91-42aa-a206-a70e2db7b84f&amp;name=triumeq-spl-graphic-01.jpg">
</div>
<p>Abacavir sulfate is a white to off-white solid and is soluble in water.</p>
<p><span class="Underline">Dolutegravir</span></p>
<p>The chemical name of dolutegravir sodium is sodium (4<span class="Italics">R</span>,12a<span class="Italics">S</span>)-9-{[(2,4-difluorophenyl)methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2<span class="Italics">H</span>-pyrido[1',2':4,5]pyrazino[2,1-<span class="Italics">b</span>][1,3]oxazin-7-olate. The empirical formula is C<span class="Sub">20</span>H<span class="Sub">18</span>F<span class="Sub">2</span>N<span class="Sub">3</span>NaO<span class="Sub">5</span> and the molecular weight is 441.36 g per mol. It has the following structural formula:</p>
<div class="Figure">
<a name="id13188873"></a><img alt="dolutegravir chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2997739a-aa91-42aa-a206-a70e2db7b84f&amp;name=triumeq-spl-graphic-02.jpg">
</div>
<p>Dolutegravir sodium is a white to light yellow powder and is slightly soluble in water.</p>
<p><span class="Underline">Lamivudine</span></p>
<p>The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2â€²,3â€²-dideoxy, 3â€²-thiacytidine. It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 229.3 g per mol. It has the following structural formula:</p>
<div class="Figure">
<a name="id2743567"></a><img alt="Epivir Chem Struc" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2997739a-aa91-42aa-a206-a70e2db7b84f&amp;name=triumeq-spl-graphic-03.jpg">
</div>
<p>Lamivudine is a white to off-white crystalline solid and is soluble in water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_cca7b33b-9a57-49ad-ad58-4adb4664d2d1"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_bb92bf86-4de0-4ed9-b692-76b4904563cc"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">TRIUMEQ is an HIV-1 antiviral agent <span class="Italics">[see Microbiology (12.4)].</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_2a057a5c-33c1-4c56-9f29-b6c2929f8930"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Underline">Effects on Electrocardiogram</span></p>
<p>A thorough QT trial has been conducted for dolutegravir. Neither the effects of abacavir nor lamivudine as single entities or the combination of abacavir, dolutegravir, and lamivudine on the QT interval have been evaluated.</p>
<p>In a randomized, placebo-controlled, cross-over trial, 42Â healthy subjects received single-dose oral administrations of placebo, dolutegravir 250â€‘mg suspension (exposures approximately 3â€“fold of the 50-mg once-daily dose at steady state), and moxifloxacin 400Â mg (active control) in random sequence. After baseline and placebo adjustment, the maximum mean QTc change based on Fridericia correction method (QTcF) for dolutegravir was 2.4Â msec (1-sided 95% upper CI: 4.9Â msec). Dolutegravir did not prolong the QTc interval over 24 hours postdose.</p>
<p><span class="Underline">Effects on Renal Function</span></p>
<p>The effect of dolutegravir on renal function was evaluated in an open-label, randomized, 3-arm, parallel, placebo-controlled trial in healthy subjects (nÂ =Â 37) who received dolutegravir 50Â mg once daily (nÂ =Â 12), dolutegravir 50 mg twice daily (nÂ =Â 13), or placebo once daily (nÂ =Â 12) for 14Â days. A decrease in creatinine clearance, as determined by 24-hour urine collection, was observed with both doses of dolutegravir after 14 days of treatment in subjects who received 50Â mg once daily (9% decrease) and 50Â mg twice daily (13% decrease). Neither dose of dolutegravir had a significant effect on the actual glomerular filtration rate (determined by the clearance of probe drug, iohexol) or effective renal plasma flow (determined by the clearance of probe drug, para-amino hippurate) compared with the placebo.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_0cce10ff-903c-47dd-8138-7f5bea219743"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Pharmacokinetics in Adults</span></p>
<p>One TRIUMEQ tablet was bioequivalent to one dolutegravir (TIVICAY) tablet (50Â mg) plus one abacavir and lamivudine fixed-dose combination tablet (EPZICOM) under fasted conditions in healthy subjects (nÂ =Â 62).</p>
<p><span class="Italics">Abacavir:</span> Following oral administration, abacavir is rapidly absorbed and extensively distributed. After oral administration of a single dose of 600 mg of abacavir in 20 subjects, C<span class="Sub">max</span> was 4.26Â Â±Â 1.19 mcg per mL (meanÂ Â±Â SD) and AUC<span class="Sub">âˆž</span> was 11.95Â Â±Â 2.51Â mcgâ€¢hour per mL. Binding of abacavir to human plasma proteins is approximately 50% and was independent of concentration. Total blood and plasma drug-related radioactivity concentrations are identical, demonstrating that abacavir readily distributes into erythrocytes. The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase to form the 5â€²-carboxylic acid and glucuronyl transferase to form the 5â€²-glucuronide. In single-dose trials, the observed elimination half-life (t<span class="Sub">1/2</span>) was 1.54Â Â±Â 0.63 hours. After intravenous administration, total clearance was 0.80Â Â±Â 0.24 L per hour per kg (meanÂ Â±Â SD).</p>
<p><span class="Italics">Dolutegravir:</span> Following oral administration of dolutegravir, peak plasma concentrations were observed 2 to 3 hours postdose. With once-daily dosing, pharmacokinetic steady state is achieved within approximately 5Â days with average accumulation ratios for AUC, C<span class="Sub">max</span>, and C<span class="Sub">24Â h</span> ranging from 1.2 to 1.5. Dolutegravir is a P-glycoprotein substrate in vitro. The absolute bioavailability of dolutegravir has not been established. Dolutegravir is highly bound (greater than or equal to 98.9%) to human plasma proteins based on in vivo data and binding is independent of plasma concentration of dolutegravir. The apparent volume of distribution (Vd/F) following 50-mg once-daily administration is estimated at 17.4 L based on a population pharmacokinetic analysis. </p>
<p>Dolutegravir is primarily metabolized via UGT1A1 with some contribution from CYP3A. After a single oral dose of [<span class="Sup">14</span>C] dolutegravir, 53% of the total oral dose is excreted unchanged in the feces. Thirty-one percent of the total oral dose is excreted in the urine, represented by an ether glucuronide of dolutegravir (18.9% of total dose), a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose), and its hydrolytic N-dealkylation product (3.6% of total dose). Renal elimination of unchanged drug was less than 1% of the dose. Dolutegravir has a terminal half-life of approximately 14Â hours and an apparent clearance (CL/F) of 1.0Â L per hour based on population pharmacokinetic analyses.</p>
<p>The pharmacokinetic properties of dolutegravir have been evaluated in healthy adult subjects and HIVâ€‘1â€‘infected adult subjects. Exposure to dolutegravir was generally similar between healthy subjects and HIVâ€‘1â€‘infected subjects. </p>
<p><span class="Bold">Table 6. Dolutegravir Steady-state Pharmacokinetic Parameter Estimates in HIV-1â€“ Infected Adults</span></p>
<table width="100%">
<col width="46%">
<col width="54%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">50 mg Once Daily</span><br><span class="Bold">Geometric Mean (%CV)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC<span class="Sub">(0-24) </span>(mcgâ€¢h/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">53.6 (27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">max</span> (mcg/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3.67 (20)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">min </span>(mcg/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.11 (46)</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Cerebrospinal Fluid (CSF):</span> In 11 treatment-naÃ¯ve subjects on dolutegravir 50 mg daily plus abacavir/lamivudine, the median dolutegravir concentration in CSF was 18 ng per mL (range: 4 ng per mL to 23.2 ng per mL) 2 to 6 hours postdose after 2 weeks of treatment. The clinical relevance of this finding has not been established. </p>
<p><span class="Italics">Lamivudine:</span> Following oral administration, lamivudine is rapidly absorbed and extensively distributed. After multiple-dose oral administration of lamivudine 300 mg once daily for 7 days to 60 healthy subjects, steady-state C<span class="Sub">max</span> (C<span class="Sub">max,ss</span>) was 2.04Â Â±Â 0.54Â mcg per mL (meanÂ Â±Â SD) and the 24-hour steady-state AUC (AUC<span class="Sub">24,ss</span>) was 8.87Â Â±Â 1.83 mcgâ€¢hour per mL. Binding to plasma protein is low. Approximately 70% of an intravenous dose of lamivudine is recovered as unchanged drug in the urine. Metabolism of lamivudine is a minor route of elimination. In humans, the only known metabolite is the trans-sulfoxide metabolite (approximately 5% of an oral dose after 12Â hours). In most single-dose trials in HIVâ€“1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-life (t<span class="Sub">Â½</span>) ranged from 5 to 7 hours. In HIV-1-infected subjects, total clearance was 398.5Â Â±Â 69.1 mL per min (meanÂ Â±Â SD).</p>
<p><span class="Underline">Effect of Food on Oral Absorption</span></p>
<p>TRIUMEQ may be taken with or without food. Overall, when compared with fasted conditions, administration of TRIUMEQ to healthy adult subjects with a high-fat meal (53% fat, 869 calories) resulted in decreased C<span class="Sub">max </span>for abacavir and increased C<span class="Sub">max </span>and AUC for dolutegravir. Lamivudine exposures were not affected by food. With a high-fat meal, the C<span class="Sub">max</span> of abacavir decreased 23% and the C<span class="Sub">max </span>and AUC of dolutegravir increased 37% and 48%, respectively.</p>
<p><span class="Underline">Special Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the combination of abacavir, dolutegravir, and lamivudine has not been evaluated (see the U.S. prescribing information for the individual abacavir, dolutegravir and lamivudine components).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the combination of abacavir, dolutegravir, and lamivudine has not been evaluated (see the U.S. prescribing information for the individual abacavir, dolutegravir and lamivudine components).</p>
<p><span class="Italics">Pediatric Patients: </span>The pharmacokinetics of the combination of abacavir, dolutegravir, and lamivudine in pediatric subjects have not been established.</p>
<p><span class="Italics">Geriatric Patients:</span> Population analyses using pooled pharmacokinetic data from adult trials indicated age had no clinically relevant effect on the pharmacokinetics of dolutegravir. The pharmacokinetics of abacavir or lamivudine have not been studied in subjects older than 65Â years.</p>
<p><span class="Italics">Gender:</span> There are no significant or clinically relevant gender differences in the pharmacokinetics of the individual components (dolutegravir, abacavir, or lamivudine) based on the available information that was analyzed for each of the individual components.</p>
<p><span class="Italics">Race:</span> There are no significant or clinically relevant racial differences in pharmacokinetics of the individual components (dolutegravir, abacavir, or lamivudine) based on the available information that was analyzed for each of the individual components.</p>
<p><span class="Underline">Drug Interactions</span></p>
<p>The drug interaction trials described were conducted with dolutegravir, abacavir, and/or lamivudine as single entities; no drug interaction trials have been conducted using the combination of abacavir, dolutegravir, and lamivudine. No clinically significant drug interactions are expected between dolutegravir, abacavir, and lamivudine. </p>
<p>Dosing recommendations as a result of established and other potentially significant drug-drug interactions with dolutegravir or abacavir are provided in Section 7.3 <span class="Italics">[see Drug Interactions (7)]</span>.</p>
<p><span class="Bold">Table 7. Summary of Effect of Dolutegravir on the Pharmacokinetics of Coadministered Drugs</span></p>
<table width="100%">
<col width="21%">
<col width="16%">
<col width="5%">
<col width="19%">
<col width="20%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Coadministered Drug(s)</span></p>
<p><span class="Bold">and Dose(s)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Dose of Dolutegravir</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold">Geometric Mean Ratio (90% CI) of Pharmacokinetic Parameters of Coadministered Drug with/without Dolutegravir</span><br><span class="Bold">No Effect = 1.00</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">C<span class="Sub">Ï„ </span>or C<span class="Sub">24</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Ethinyl estradiol<br>0.035Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.99<br>(0.91 to 1.08)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.03<br>(0.96 to 1.11)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.02<br>(0.93 to 1.11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Metformin<br>500 mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50 mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.66<br>(1.53 to 1.81)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.79<br>(1.65 to 1.93)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â€”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Metformin<br>500 mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.11<br>(1.91 to 2.33)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.45<br>(2.25 to 2.66)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â€”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Methadone<br>16 to 150 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.00<br>(0.94 to 1.06)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.98<br>(0.91 to 1.06)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.99<br>(0.91 to 1.07)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Midazolam<br>3 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â€”</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.95<br>(0.79 to 1.15)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â€”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Norelgestromin<br>0.25 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.89<br>(0.82 to 0.97)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.98<br>(0.91 to 1.04)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.93<br>(0.85 to 1.03)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Rilpivirine<br>25 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50 mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.10<br>(0.99 to 1.22)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.06<br>(0.98 to 1.16)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.21<br>(1.07 to 1.38)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Tenofovir disoproxil fumarate<br>300 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.09<br>(0.97 to 1.23)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.12<br>(1.01 to 1.24)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.19<br>(1.04 to 1.35)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>The number of subjects represents the maximum number of subjects that were evaluated.</p>
<p><span class="Bold">TableÂ 8. Summary of Effect of Coadministered Drugs on the Pharmacokinetics of Dolutegravir </span></p>
<table width="100%">
<col width="26%">
<col width="16%">
<col width="5%">
<col width="18%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Coadministered Drug(s)</span></p>
<p><span class="Bold">and Dose(s)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Dose of Dolutegravir</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold">Geometric Mean Ratio (90% CI) of Dolutegravir Pharmacokinetic Parameters with/without Coadministered Drugs</span><br><span class="Bold">No Effect = 1.00</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">C<span class="Sub">Ï„ </span>or C<span class="Sub">24</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Atazanavir <br>400Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.50<br>(1.40 to 1.59)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.91<br>(1.80 to 2.03)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.80<br>(2.52 to 3.11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Atazanavir/ritonavir<br>300/100Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.34<br>(1.25 to 1.42)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.62<br>(1.50 to 1.74)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.21<br>(1.97 to 2.47)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Darunavir/ritonavir<br>600/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.89<br>(0.83 to 0.97)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.78<br>(0.72 to 0.85)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.62<br>(0.56 to 0.69)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Efavirenz <br>600Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.61<br>(0.51 to 0.73)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.43<br>(0.35 to 0.54)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.25<br>(0.18 to 0.34)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Etravirine<br>200Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.48<br>(0.43 to 0.54)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.29<br>(0.26 to 0.34)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.12<br>(0.09 to 0.16)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Etravirine + darunavir/ritonavir <br>200Â mg + 600/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.88<br>(0.78 to 1.00)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.75<br>(0.69 to 0.81)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.63<br>(0.52 to 0.76)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Etravirine + lopinavir/ritonavir <br>200Â mg + 400/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.07<br>(1.02 to 1.13)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.11<br>(1.02 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.28<br>(1.13 to 1.45)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Fosamprenavir/ritonavir<br>700Â mg/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.76<br>(0.63 to 0.92)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.65<br>(0.54 to 0.78)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.51<br>(0.41 to 0.63)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Lopinavir/ritonavir<br>400/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.00<br>(0.94 to 1.07)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.97<br>(0.91 to 1.04)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.94<br>(0.85 to 1.05)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Rilpivirine<br>25 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.13 <br>(1.06 to 1.21)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.12 <br>(1.05 to 1.19)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.22 <br>(1.15 to 1.30)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Tenofovir<br>300Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.97<br>(0.87 to 1.08)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.01<br>(0.91 to 1.11)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">0.92</p>
<p>(0.82 to 1.04)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Tipranavir/ritonavir<br>500/200Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.54<br>(0.50 to 0.57)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.41<br>(0.38 to 0.44)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.24<br>(0.21 to 0.27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Antacid (Maalox<span class="Sup">Â®</span>)<br>simultaneous administration</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.28<br>(0.23 to 0.33)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.26<br>(0.22 to 0.32)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.26<br>(0.21 to 0.31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Antacid (Maalox<span class="Sup">Â®</span>) <br>2 h after dolutegravir</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.82<br>(0.69 to 0.98)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.74<br>(0.62 to 0.90)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.70<br>(0.58 to 0.85)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Boceprevir<br>800Â mg every 8 h</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.05<br>(0.96 to 1.15)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.07<br>(0.95 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.08<br>(0.91 to 1.28)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Calcium carbonate 1,200 mg<br>simultaneous administration (fasted)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.63<br>(0.50 to 0.81)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.61<br>(0.47 to 0.80)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.61<br>(0.47 to 0.80)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Calcium carbonate 1,200 mg<br>simultaneous administration (fed)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.07<br>(0.83 to 1.38)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.09<br>(0.84 to 1.43)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.08<br>(0.81 to 1.42)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Calcium carbonate 1,200 mg<br>2 h after dolutegravir</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.00<br>(0.78 to 1.29)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.94<br>(0.72 to 1.23)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.90<br>(0.68 to 1.19)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Carbamazepine<br>300 mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16<span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.67<br>(0.61 to 0.73)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.51<br>(0.48 to 0.55)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.27<br>(0.24 to 0.31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Ferrous fumarate 324 mg<br>simultaneous administration (fasted)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.43<br>(0.35 to 0.52)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.46<br>(0.38 to 0.56)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.44<br>(0.36 to 0.54)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Ferrous fumarate 324 mg<br>simultaneous administration (fed)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.03<br>(0.84 to 1.26)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.98<br>(0.81 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.00<br>(0.81 to 1.23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Ferrous fumarate 324 mg<br>2 h after dolutegravir</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.99<br>(0.81 to 1.21)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.95<br>(0.77 to 1.15)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.92<br>(0.74 to 1.13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Multivitamin (One-A-Day<span class="Sup">Â®</span>)<br>simultaneous administration</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.65<br>(0.54 to 0.77)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.67<br>(0.55 to 0.81)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.68<br>(0.56 to 0.82)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Omeprazole<br>40Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.92<br>(0.75 to 1.11)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.97<br>(0.78 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.95<br>(0.75 to 1.21)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Prednisone<br>60Â mg once daily with taper</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.06<br>(0.99 to 1.14)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.11<br>(1.03 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.17<br>(1.06 to 1.28)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Rifampin<span class="Sup">a</span><br>600 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.57<br>(0.49 to 0.65)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.46<br>(0.38 to 0.55)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.28<br>(0.23 to 0.34)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Rifampin<span class="Sup">b</span><br>600 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.18<br>(1.03 to 1.37)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.33<br>(1.15 to 1.53)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.22<br>(1.01 to 1.48)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Rifabutin<br>300 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.16<br>(0.98 to 1.37)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.95<br>(0.82 to 1.10)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.70<br>(0.57 to 0.87)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Comparison is rifampin taken with dolutegravir 50Â mg twice daily compared with dolutegravir 50Â mg twice daily.</p>
<p><span class="Sup">b </span>Comparison is rifampin taken with dolutegravir 50Â mg twice daily compared with dolutegravir 50Â mg once daily.</p>
<p><span class="Sup">c</span> The number of subjects represents the maximum number of subjects that were evaluated.</p>
<p><span class="Italics">Abacavir or Lamivudine: </span>The drug interactions described are based on trials conducted with abacavir or lamivudine as single entities.</p>
<p><span class="Italics">Ethanol: </span>Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of abacavir causing an increase in overall exposure.</p>
<p><span class="Italics">Interferon Alfa:</span> There was no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between lamivudine and interferon alfa in a trial of 19 healthy male subjects.</p>
<p><span class="Italics">Methadone:</span> In a trial of 11Â HIVâ€‘1â€‘infected subjects receiving methadone-maintenance therapy (40Â mg and 90Â mg daily), with 600Â mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI: 6% to 42%) <span class="Italics">[see Drug Interactions (7.3)]. </span>The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.</p>
<p><span class="Italics">Ribavirin:</span> InÂ vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (nÂ =Â 18), stavudine (nÂ =Â 10), or zidovudine (nÂ =Â 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected subjects <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
<p><span class="Italics">Abacavir, Lamivudine, Zidovudine: </span>Fifteen HIVâ€‘1-infected subjects were enrolled in a crossover-designed drug interaction trial evaluating single doses of abacavir (600 mg), lamivudine (150 mg), and zidovudine (300 mg) alone or in combination. Analysis showed no clinically relevant changes in the pharmacokinetics of abacavir with the addition of lamivudine or zidovudine or the combination of lamivudine and zidovudine. Lamivudine exposure (AUC decreased 15%) and zidovudine exposure (AUC increased 10%) did not show clinically relevant changes with concurrent abacavir.</p>
<p><span class="Italics">Lamivudine and Zidovudine: </span>No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12 asymptomatic HIVâ€‘1-infected adult patients given a single dose of zidovudine (200 mg) in combination with multiple doses of lamivudine (300 mg every 12 h).</p>
<p>The effects of other coadministered drugs on abacavir or lamivudine are provided in Table 9.</p>
<p><span class="Bold">TableÂ 9. Effect of Coadministered Drugs on Abacavir or Lamivudine </span></p>
<table width="100%">
<col width="24%">
<col width="14%">
<col width="4%">
<col width="11%">
<col width="20%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Coadministered Drug and Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Drug and Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">Concentrations of Abacavir or Lamivudine</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Concentration of Coadministered Drug</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Variability</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Ethanol</p>
<p>0.7 g/kg </p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Abacavir</p>
<p>Single 600Â mg </p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†‘41%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>
<p>35% to 48%</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†”<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nelfinavir</p>
<p>750Â mgÂ every 8 h x 7 to 10Â days</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Lamivudine</p>
<p>Single 150Â mg </p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†‘10%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>
<p>1% to 20%</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Trimethoprim 160Â mg/</p>
<p>Sulfamethoxazole</p>
<p>800Â mg daily x 5Â days</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Lamivudine</p>
<p>Single 300Â mg </p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†‘43%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>
<p>32% to 55%</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
</tbody>
</table>
<p>â†‘Â =Â Increase; â†”Â =Â no significant change; AUCÂ =Â area under the concentration versus time curve; CIÂ =Â confidence interval.</p>
<p><span class="Sup">a</span> The drug-drug interaction was only evaluated in males.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="ID_0a8d29f6-1841-4f83-91ba-cf80028be6e1"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action</span></p>
<p><span class="Italics">Dolutegravir:</span> Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for the HIV replication cycle. Strand transfer biochemical assays using purified recombinant HIV-1 integrase and pre-processed substrate DNA resulted in IC<span class="Sub">50 </span>values of 2.7Â nM and 12.6Â nM.</p>
<p><span class="Italics">Abacavir:</span> Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5â€²-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.</p>
<p><span class="Italics">Lamivudine:</span> Lamivudine is a synthetic nucleoside analogue. Intracellularly lamivudine is phosphorylated to its active 5â€²-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue.</p>
<p><span class="Underline">Antiviral Activity in Cell Culture</span></p>
<p><span class="Italics">Dolutegravir:</span> Dolutegravir exhibited antiviral activity against laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of wild-type HIV-1 with mean concentration of drug necessary to effect viral replication by 50Â percent (EC<span class="Sub">50</span>) values of 0.5Â nM (0.21Â ng per mL) to 2.1Â nM (0.85Â ng per mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells. Dolutegravir exhibited antiviral activity against 13 clinically diverse clade B isolates with a median EC<span class="Sub">50</span> value of 0.54Â nM (range: 0.41 to 0.60Â nM) in a viral susceptibility assay using the integrase coding region from clinical isolates. Dolutegravir demonstrated antiviral activity in cell culture against a panel of HIVâ€‘1 clinical isolates with median EC<span class="Sub">50</span> values of 0.18Â nM (nÂ =Â 3, range: 0.09 to 0.5Â nM), 0.08Â nM (nÂ =Â 5, range: 0.05 to 2.14Â nM) 0.12Â nM (nÂ =Â 4, range: 0.05 to 0.51Â nM), 0.17Â nM (nÂ =Â 3, range: 0.16 to 0.35Â nM), 0.24Â nM (nÂ =Â 3, range: 0.09 to 0.32Â nM), 0.17Â nM (range: 0.07 to 0.44Â nM), 0.2Â nM (nÂ =Â 3, range: 0.02 to 0.87Â nM), and 0.42Â nM (nÂ =Â 3, range: 0.41 to 1.79Â nM) for clades A, B, C, D, E, F, and G, and group O viruses, respectively. Dolutegravir EC<span class="Sub">50</span> values against three HIV-2 clinical isolates in PBMC assays ranged from 0.09Â nM to 0.61Â nM.</p>
<p><span class="Italics">Abacavir:</span> The antiviral activity of abacavir against HIV-1 was assessed in a number of cell lines including in primary monocytes/macrophages and PBMCs. EC<span class="Sub">50</span> values ranged from 3.7 to 5.8Â microM (1Â microMÂ =Â 0.28Â mcg per mL) and 0.07 to 1.0 microM against HIV-1<span class="Sub">IIIB</span> and HIV-1<span class="Sub">BaL</span>, respectively, and the mean EC<span class="Sub">50</span> value was 0.26Â Â±Â 0.18Â microM against 8 clinical isolates. The median EC<span class="Sub">50</span> values of abacavir were 344Â nM (range: 14.8 to 676Â nM), 16.9Â nM (range: 5.9 to 27.9Â nM), 8.1Â nM (range: 1.5 to 16.7Â nM), 356Â nM (range: 35.7 to 396Â nM), 105Â nM (range: 28.1 to 168Â nM), 47.6Â nM (range: 5.2 to 200Â nM), 51.4Â nM (range: 7.1 to 177Â nM), and 282Â nM (range: 22.4 to 598Â nM) against HIVâ€‘1 clades A-G and group O viruses (nÂ =Â 3 except nÂ =Â 2 for clade B), respectively. The EC<span class="Sub">50</span> values against HIVâ€‘2 isolates (nÂ =Â 4), ranged from 0.024 to 0.49Â microM.</p>
<p><span class="Italics">Lamivudine:</span> The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines including monocytes and PBMCs using standard susceptibility assays. EC<span class="Sub">50</span> values were in the range of 0.003 to 15Â microM (1Â microMÂ =Â 0.23Â mcg per mL). The median EC<span class="Sub">50</span> values of lamivudine  were 60Â nM (range: 20 to 70Â nM), 35Â nM (range: 30 to 40Â nM), 30 nM (range: 20 to 90Â nM), 20Â nM (range: 3 to 40Â nM), 30Â nM (range: 1 to 60 nM), 30Â nM (range: 20 to 70 nM), 30Â nM (range: 3 to 70Â nM), and 30Â nM (range: 20 to 90Â nM) against HIVâ€‘1 clades A-G and group O viruses (nÂ =Â 3 except nÂ =Â 2 for clade B) respectively. The EC<span class="Sub">50</span> values against HIVâ€‘2 isolates (nÂ =Â 4) from 0.003 to 0.120Â microM in PBMCs. Ribavirin (50 microM) used in the treatment of chronic HCV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> decreased the anti-HIV-1 activity of lamivudine by 3.5-fold in MT-4 cells.</p>
<p><span class="Underline">Antiviral Activity in Combination with Other Antiviral Agents</span></p>
<p>Neither dolutegravir, abacavir, nor lamivudine were antagonistic to all tested anti-HIV agents. See full prescribing information for ZIAGEN (abacavir), TIVICAY (dolutegravir), and EPIVIR (lamivudine).</p>
<p><span class="Underline">Resistance in Cell Culture</span></p>
<p><span class="Italics">Dolutegravir:</span> Dolutegravir-resistant viruses were selected in cell culture starting from different wild-type HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clades. Amino acid substitutions E92Q, G118R, S153F or Y, G193E or R263K emerged in different passages and conferred decreased susceptibility to dolutegravir of up to 4-fold. </p>
<p><span class="Italics">Abacavir and Lamivudine</span>: HIV-1 isolates with reduced susceptibility to the combination of abacavir and lamivudine have been selected in cell culture with amino acid substitutions K65R, L74V, Y115F, and M184V/I in HIV-1 RT. M184V or I substitutions resulted in high-level resistance to lamivudine and approximately 2-fold decrease in susceptibility to abacavir. Substitutions K65R, L74M, or Y115F with M184V or I conferred a 7- to 8-fold reduction in abacavir susceptibility, and combinations of three substitutions were required to confer more than an 8-fold reduction in susceptibility.</p>
<p><span class="Underline">Resistance in Clinical Subjects</span></p>
<p><span class="Italics">Dolutegravir:</span> No subjects in the treatment arm receiving dolutegravir + EPZICOM of SINGLE (treatment-naÃ¯ve trial) had a detectable decrease in susceptibility to dolutegravir or background NRTIs in the resistance analysis subset (nÂ =Â 8 with HIV-1 RNA greater than 400Â copies per mL at failure or last visit through Week 96 and having resistance data). One subject in SINGLE with 275Â copies per mL HIV-1 RNA had a treatment-emergent integrase substitution (E157Q/P) detected at Week 24, but no corresponding decrease in dolutegravir susceptibility. No treatment-emergent genotypic resistance to abacavir and lamivudine, components of TRIUMEQ, was observed in the arm receiving dolutegravir + EPZICOM in the SINGLE trial.</p>
<p><span class="Underline">Cross-resistance</span></p>
<p><span class="Italics">Dolutegravir:</span> The single INSTI-resistance substitutions T66K, I151L, and S153Y conferred a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.3-fold to 3.6-fold from reference). Combinations of multiple substitutions T66K/L74M, E92Q/N155H, G140C/Q148R, G140S/Q148H, R or K, Q148R/N155H, T97A/G140S/Q148, and substitutions at E138/G140/Q148 showed a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.5-fold to 21-fold from reference). In HIV-2 mutants, combinations of substitutions A153G/N155H/S163G and E92Q/T97A/N155H/S163D conferred 4-fold decreases in dolutegravir susceptibility, and E92Q/N155H and G140S/Q148R showed 8.5-fold and 17-fold decreases in dolutegravir susceptibility, respectively.</p>
<p><span class="Italics">Abacavir and Lamivudine:</span> Crossâ€‘resistance has been observed among NRTIs. The combination of abacavir/lamivudine has demonstrated decreased susceptibility to viruses with a K65R substitution with or without an M184V/I substitution, viruses with L74V plus the M184V/I substitution, and viruses with thymidine analog mutation (TAM) substitutions (M41L, D67N, K70R, L210W, T215Y/F, K219 E/R/H/Q/N) plus M184V. An increasing number of TAMs is associated with a progressive reduction in abacavir susceptibility.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_0659d06b-bb62-4d06-932a-c897374208f9"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_8ea35738-bbb2-4959-ae6e-2ea3f1396d60"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenicity</span></p>
<p><span class="Italics">Dolutegravir:</span> Two-year carcinogenicity studies in mice and rats were conducted with dolutegravir. Mice were administered doses of up to 500Â mg per kg, and rats were administered doses of up to 50Â mg per kg. In mice, no significant increases in the incidence of drug-related neoplasms were observed at the highest doses tested, resulting in dolutegravir AUC exposures approximately 26-fold higher than those in humans at the recommended dose of 50Â mg once daily. In rats, no increases in the incidence of drug-related neoplasms were observed at the highest dose tested, resulting in dolutegravir AUC exposures 17-fold and 30-fold higher in males and females, respectively, than those in humans at the recommended dose of 50Â mg once daily.</p>
<p><span class="Italics">Abacavir:</span> Abacavir was administered orally at 3Â dosage levels to separate groups of mice and rats in 2â€‘year carcinogenicity studies. Results showed an increase in the incidence of malignant and nonâ€‘<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>. <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">Malignant tumors</span> occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver of female rats. In addition, nonâ€‘<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> also occurred in the liver and thyroid gland of female rats. These observations were made at systemic exposures in the range of 7 to 28Â times the human exposure at the recommended dose of 600Â mg.</p>
<p><span class="Italics">Lamivudine:</span> Longâ€‘term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 12Â times (mice) and 57Â times (rats) the human exposures at the recommended dose of 300Â mg.</p>
<p><span class="Underline">Mutagenicity</span></p>
<p><span class="Italics">Dolutegravir:</span> Dolutegravir was not genotoxic in the bacterial reverse mutation assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, or in the in vivo rodent micronucleus assay.</p>
<p><span class="Italics">Abacavir:</span> Abacavir induced chromosomal aberrations both in the presence and absence of metabolic activation in an inÂ vitro cytogenetic study in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Abacavir was mutagenic in the absence of metabolic activation, although it was not mutagenic in the presence of metabolic activation in an L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay. Abacavir was clastogenic in males and not clastogenic in females in an inÂ vivo mouse bone marrow micronucleus assay. Abacavir was not mutagenic in bacterial mutagenicity assays in the presence and absence of metabolic activation.</p>
<p><span class="Italics">Lamivudine:</span> Lamivudine was mutagenic in an L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Lamivudine was not mutagenic in a microbial mutagenicity assay, in an inÂ vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.</p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p>Dolutegravir, abacavir, or lamivudine did not affect male or female fertility in rats at doses associated with exposures approximately 44, 9, or 112 times (respectively) higher than the exposures in humans at the doses of 50Â mg, 600Â mg, and 300Â mg (respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c70ae023-5600-41bf-8c15-fbef99a9aba3"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Myocardial degeneration</span> was found in mice and rats following administration of abacavir for 2Â years. The systemic exposures were equivalent to 7 to 21Â times the expected systemic exposure in humans at a dose of 600Â mg. The clinical relevance of this finding has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_8895ad2d-fbf4-4f7c-9676-c496aaf50618"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_31b2aa54-1d1e-4b30-b430-6d48d81e29e1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Subjects</h2>
<p class="First">The efficacy of TRIUMEQ is supported by data from a randomized, controlled trial in antiretroviral treatment-naÃ¯ve subjects, SINGLE (ING114467) and other trials in treatment-naÃ¯ve subjects. See full prescribing information for TIVICAY. The efficacy of dolutegravir, in combination with at least two active background regimens in treatment-experienced, INSTI-naÃ¯ve subjects is supported by data from SAILING (ING111762) (refer to the prescribing information for TIVICAY).</p>
<p><span class="Underline">Treatment-naÃ¯ve Subjects</span></p>
<p>In SINGLE, 833 subjects were randomized and received at least 1 dose of either TIVICAY 50Â mg once daily with fixed-dose abacavir and lamivudine (EPZICOM) or fixed-dose efavirenz/emtricitabine/tenofovir disoproxil fumarate (ATRIPLA). At baseline, the median age of subjects was 35 years, 16% female, 32% non-white, 7% had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was excluded), 4% were CDC Class C (AIDS), 32% had HIVâ€‘1 RNA greater than 100,000Â copies per mL, and 53% had CD4+Â cell count less than 350Â cells per mm<span class="Sup">3</span>; these characteristics were similar between treatment groups. Week 96 outcomes  for SINGLE are provided in TableÂ 10.</p>
<p><span class="Bold">Table 10. Virologic Outcomes of Randomized Treatment in SINGLE at 96Â Weeks (Snapshot Algorithm)</span></p>
<table width="100%">
<col width="54%">
<col width="22%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">TIVICAY + EPZICOM Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 414)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">ATRIPLA</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 419)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">HIV</span>â€‘<span class="Bold">1 RNA &lt;50Â copies/mL </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">80%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">72%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Treatment difference<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">8.0% (95% CI: 2.3%, 13.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Virologic nonresponse<span class="Sup">b</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">No virologic data </span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">12%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">20%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Reasons</p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Discontinued study/study drug due to adverse event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">c</span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">11%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Discontinued study/study drug for other reasons<span class="Sup">d</span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">9%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Missing data during window but on study</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Proportion (%) of Subjects with HIV</span>â€‘<span class="Bold">1 RNA &lt;50Â copies/mL by Baseline Category</span></p></td></tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Plasma viral load (copies/mL)<span class="Sup">e</span></span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">â‰¤100,000</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">85%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">73%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">&gt;100,000</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">71%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">72%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Gender</span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Male </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">81%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">75%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Female </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">76%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Race </span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">White </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">79%</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">77%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">African-American/African Heritage/Other</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">83%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">62%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">aÂ </span>Adjusted for pre-specified stratification factors.</p>
<p><span class="Sup">bÂ </span>Includes subjects who discontinued prior to Week 96 for lack or loss of efficacy, and subjects who were HIV-1 RNA Â Â greater than or equal to 50Â copies per mL in the Week 96 window. </p>
<p><span class="Sup">cÂ </span>Includes subjects who discontinued due to an adverse event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at any time point from Day 1 through the Week 96 Â Â window if this resulted in no virologic data on treatment during the Week 96 window. </p>
<p><span class="Sup">dÂ </span>Other includes reasons such as withdrew consent, loss to follow-up, moved, and protocol deviation.</p>
<p><span class="Sup">e</span>Â The proportion of subjects who had no virologic data due to reasons such as withdrew consent, lost to follow-up, moved, Â Â and protocol deviation was 10% (TIVICAYÂ +Â EPZICOM) and 6% (ATRIPLA) in the greater than 100,000â€“copies-per-Â Â mL group and 8% and 9% (respectively) in the less than or equal to 100,000â€“copies-per-mL group.</p>
<p>Treatment differences were maintained across baseline characteristics including CD4+Â cell count, age, gender, and race. The adjusted mean changes in CD4+ cell counts from baseline were 325Â cells per mm<span class="Sup">3</span> in the group receiving TIVICAYÂ +Â EPZICOM and 281Â cells per mm<span class="Sup">3</span> for the ATRIPLA group at 96Â weeks. The adjusted difference between treatment arms and 95% CI was 44.0Â cells per mm<span class="Sup">3</span> (14.3Â cells per mm<span class="Sup">3</span>, 73.6Â cells per mm<span class="Sup">3</span>) (adjusted for pre-specified stratification factors: baseline HIVâ€‘1 RNA, baseline CD4+ cell count, and multiplicity).</p>
<p><span class="Underline">Treatment-experienced</span></p>
<p>In SAILING, there were 715 subjects included in the efficacy and safety analyses (see full prescribing information for TIVICAY). At Week 48, 71% of subjects randomized to TIVICAY plus background regimen versus 64% of subjects randomized to raltegravir plus background regimen had HIVâ€‘1 RNA less than 50 copies per mL (treatment difference and 95% CI: 7.4% [0.7%, 14.2%]).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_14c98c96-1165-4e2f-8bb3-91b7366d3c37"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">TRIUMEQ tablets, 600Â mg of abacavir as abacavir sulfate, 50Â mg of dolutegravir as dolutegravir sodium, and 300Â mg lamivudine, are purple, oval, film-coated, biconvex tablets debossed with â€œ572 TrÄ±â€? on one side.</p>
<dl>
<dt>Â </dt>
<dd>Bottle of 30 with child-resistant closure	NDC 49702-231-13.</dd>
</dl>
<p>Store and dispense in the original package, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant.</p>
<p>Store at 25<span class="Bold">Â°</span>C (77<span class="Bold">Â°</span>F); excursions permitted 15<span class="Bold">Â°</span> to 30<span class="Bold">Â°</span>C (59<span class="Bold">Â°</span> to 86<span class="Bold">Â°</span>F). [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_9a1e0cea-6105-4f1b-b530-ea505fbc424a"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>
<p><span class="Underline">Drug Interactions</span></p>
<p>Do not coadminister TRIUMEQ with dofetilide (TIKOSYN<span class="Sup">Â®</span>) because the interaction between dofetilide and dolutegravir can result in potentially life-threatening adverse events <span class="Italics">[see Contraindications (4)]</span>. Patients should be advised to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></span></p>
<p>Inform patients:</p>
<dl>
<dt>â€¢</dt>
<dd>that a Medication Guide and Warning Card summarizing the symptoms of the abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> and other product information will be dispensed by the pharmacist with each new prescription and refill of TRIUMEQ, and instruct the patient to read the Medication Guide and Warning Card every time to obtain any new information that may be present about TRIUMEQ. The complete text of the Medication Guide is reprinted at the end of this document.</dd>
<dt>â€¢</dt>
<dd>to carry the Warning Card with them.</dd>
<dt>â€¢</dt>
<dd>how to identify a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> <span class="Italics">[see Warnings and Precautions (5.1), Medication Guide]</span>.</dd>
<dt>â€¢</dt>
<dd>that if they develop symptoms consistent with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> they should call their healthcare provider right away to determine if they should stop taking TRIUMEQ.</dd>
<dt>â€¢</dt>
<dd>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> can worsen and lead to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if TRIUMEQ is not immediately discontinued.</dd>
<dt>â€¢</dt>
<dd>to not restart TRIUMEQ or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> because more severe symptoms can occur within hours and may include lifeâ€‘threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</dd>
<dt>â€¢</dt>
<dd>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is usually reversible if it is detected promptly and TRIUMEQ is stopped right away.</dd>
<dt>â€¢</dt>
<dd>that if they have interrupted TRIUMEQ for reasons other than symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (for example, those who have an interruption in drug supply), a serious or fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> may occur with reintroduction of abacavir.</dd>
<dt>â€¢</dt>
<dd>to not restart TRIUMEQ or any other abacavirâ€‘containing product without medical consultation and only if medical care can be readily accessed by the patient or others.</dd>
<dt>â€¢</dt>
<dd>to not restart TRIUMEQ or any other dolutegravir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to TRIUMEQ.</dd>
</dl>
<p><span class="Underline">Related Products that are Not Recommended</span></p>
<p>Inform patients that they should not take TRIUMEQ with ATRIPLA, COMBIVIR<span class="Sup">Â®</span>, COMPLERA<span class="Sup">Â®</span>, DUTREBIS<span class="Sup">â„¢</span>, EMTRIVA<span class="Sup">Â®</span>, EPIVIR, EPIVIRâ€‘HBV, EPZICOM, STRIBILD<span class="Sup">Â®</span>, TRIZIVIR, TRUVADA<span class="Sup">Â®</span>, or ZIAGEN.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span></span></p>
<p>Inform patients that some HIV medicines, including TRIUMEQ, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.2)].</span></p>
<p><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></p>
<p>Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C may be at increased risk for worsening or development of transaminase elevations with use of TRIUMEQ and advise patients to have laboratory testing before and during therapy <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</p>
<p>Advise patients coâ€‘infected with HIVâ€‘1 and HBV that worsening of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Advise patients to discuss any changes in regimen with their physician <span class="Italics">[see Warnings and Precautions (5.3)].</span></p>
<p>Inform patients with HIVâ€‘1/HCV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that hepatic decompensation (some fatal) has occurred in HIVâ€‘1/HCV co-infected patients receiving combination antiretroviral therapy for HIVâ€‘1 and interferon alfa with or without ribavirin <span class="Italics">[see Warnings and Precautions (5.4)].</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></span></p>
<p>In some patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> from previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may have been present with no obvious symptoms. Advise patients to inform their healthcare provider immediately of any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Warnings and Precautions (5.5)].</span></p>
<p><span class="Underline">Redistribution/Accumulation of Body Fat</span></p>
<p>Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</p>
<p><span class="Underline">Information about HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p>
<p>TRIUMEQ is not a cure for HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients must remain on continuous HIV therapy to control HIVâ€‘1infection and decrease HIV-related illness. Inform patients that sustained decreases in plasma HIV RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>Advise patients to remain under the care of a physician when using TRIUMEQ. </p>
<p>Advise patients to take all HIV medications exactly as prescribed. </p>
<p>Advise patients to avoid doing things that can spread HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<p>Advise patients not to re-use or share needles or other injection equipment.</p>
<p>Advise patients not to share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</p>
<p>Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</p>
<p>Female patients should be advised not to breastfeed because it is not known if TRIUMEQ can be passed to your baby in your breast milk and whether it could harm your baby. Mothers with HIVâ€‘1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</p>
<p>Instruct patients to read the Medication Guide before starting TRIUMEQ and to reread it each time the prescription is renewed. Instruct patients to inform their physician or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens. </p>
<p>Instruct patients that if they miss a dose, they should take it as soon as they remember. If they do not remember until it is within 4 hours of the time for the next dose, they should be instructed to skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed dose.</p>
<p>Instruct patients to store TRIUMEQ in the original package, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant.</p>
<p>COMBIVIR, EPIVIR, EPZICOM, TIVICAY, TRIUMEQ, TRIZIVIR, and ZIAGEN are registered trademarks of the ViiV Healthcare group of companies.</p>
<p>EPIVIR-HBV is a registered trademark of the GSK group of companies.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from </p>
<p><span class="Bold">Shire Pharmaceuticals Group plc</span></p>
<p>Basingstoke, UK</p>
<p>Â©2015 the ViiV Healthcare group of companies. All rights reserved.</p>
<p>TRM:3PI</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_9f463ed6-0bdb-4789-816d-50200886ac05"></a><a name="section-16"></a><p></p>
<table width="100%">
<col width="79%">
<col width="21%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">TRIUMEQ<span class="Sup">Â®</span> (TRI-u-meck)</span></p>
<p><span class="Bold">(abacavir, dolutegravir, and lamivudine)</span></p>
<p><span class="Bold">tablets</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">What is the most important information I should know about TRIUMEQ?</span></p>
<p><span class="Bold">TRIUMEQ can cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>)</span> that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have happened with TRIUMEQ and other abacavir-containing products. Your risk of this <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to abacavir is much higher if you have a gene variation called HLAâ€‘B*5701. Your healthcare provider can determine with a blood test if you have this gene variation.<dl>
<dt>Â </dt>
<dd><span class="Bold">If you get a symptom from 2 or more of the following groups while taking TRIUMEQ, call your healthcare provider right away to find out if you should stop taking TRIUMEQ.</span></dd>
</dl>
</dd>
<dt>Â </dt>
<dd><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Symptom</span></dd>
</dl>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Group 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Group 2Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Group 3Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abdominal (stomach area) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Group 4Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Generally ill feeling, extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or achiness</span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Group 5Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></span></p>
<dl>
<dt>Â </dt>
<dd>A list of these symptoms is on the Warning Card your pharmacist gives you. <span class="Bold">Carry this Warning Card with you at all times.</span>
</dd>
<dt>Â </dt>
<dd>
<span class="Bold">If you stop TRIUMEQ because of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, never take TRIUMEQ (abacavir, dolutegravir and lamivudine) or any other abacavirâ€‘ or dolutegravirâ€‘containing medicines (EPZICOM</span><span class="Sup">Â®</span>,<span class="Bold"> TIVICAY<span class="Sup">Â®</span>, TRIZIVIR</span><span class="Sup">Â®</span><span class="Bold">, or ZIAGEN</span><span class="Sup">Â®</span><span class="Bold">) again</span>. <dl>
<dt>â€¢</dt>
<dd>If you take TRIUMEQ or any other abacavirâ€‘containing medicine again after you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="Bold">within hours</span> you may get <span class="Bold">lifeâ€‘threatening symptoms</span> that may include <span class="Bold">very <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> </span>or <span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span>
</dd>
<dt>â€¢</dt>
<dd>If you stop TRIUMEQ for any other reason, even for a few days, and you are not allergic to TRIUMEQ, talk with your healthcare provider before taking it again. Taking TRIUMEQ again can cause a serious allergic or lifeâ€‘threatening reaction, even if you never had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to it before.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">If your healthcare provider tells you that you can take TRIUMEQ again, start taking it when you are around medical help or people who can call a healthcare provider if you need one.</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Build-up of acid in your blood (<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>). </span><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can happen in some people who take TRIUMEQ. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Bold">Call your healthcare provider right away if you get any of the following symptoms that could be signs of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>: </span>
</dd>
</dl>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â feel very weak or tiredÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</p>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â unusual (not normal) muscle painÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â feel dizzy or light-headed</p>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â trouble breathingÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â have a fast or irregular heartbeat</p>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and vomitingÂ Â Â </p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Serious liver problems </span>can happen in people who take TRIUMEQ. In some cases, these serious liver problems can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your liver may become large (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and you may develop fat in your liver (steatosis). <span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of liver problems:</span>
</dd>
</dl>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â your skin or the white part of your eyesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â loss of appetite for several days or longer</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â dark or â€œtea-coloredâ€? urineÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, aching, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> on the right side</p>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â light-colored stools (bowel movements)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â of  your stomach area</p>
<p><span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or serious liver problems if you are female, very overweight (obese), or have been taking nucleoside analogue medicines for a long time.</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Worsening of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus in people who have HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </span>If you have Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus type 1 (HIV-1) and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, your HBV may get worse (flare-up) if you stop taking TRIUMEQ. A â€œflare-upâ€? is when your HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> suddenly returns in a worse way than before. Worsening liver disease can be serious and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <dl>
<dt>â€¢</dt>
<dd>Do not run out of TRIUMEQ. Refill your prescription or talk to your healthcare provider before your TRIUMEQ is all gone.</dd>
<dt>â€¢</dt>
<dd>Do not stop TRIUMEQ without first talking to your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>If you stop taking TRIUMEQ, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your liver.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Resistant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus (HBV).</span> If you have HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus can change (mutate) during your treatment with TRIUMEQ and become harder to treat (resistant). </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Use with interferon and ribavirinâ€‘based regimens. </span>Worsening of liver disease that has caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has happened in people infected with both HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus who are taking antiretroviral medicines, and are also being treated for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C with interferon with or without ribavirin. If you are taking TRIUMEQ and interferon with or without ribavirin, tell your healthcare provider if you have any new symptoms.</dd>
</dl>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">What is TRIUMEQ?</span></p>
<p>TRIUMEQ is a prescription HIVâ€‘1 (Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus type 1) medicine used alone or with other antiretroviral medicines to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. HIV-1 is the virus that causes <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span> (AIDS). TRIUMEQ contains 3 prescription medicines, abacavir (ZIAGEN), dolutegravir (TIVICAY) and lamivudine (EPIVIR<span class="Sup">Â®</span>).</p>
<dl>
<dt>Â </dt>
<dd><dl>
<dt>â€¢</dt>
<dd>TRIUMEQ is not for use by itself in people who have or have had resistance to abacavir, dolutegravir, or lamivudine.</dd>
</dl></dd>
</dl>
<p>TRIUMEQ should not be used in children.</p>
<p><span class="Bold">When used alone or with other antiretroviral medicines to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, TRIUMEQ may help:</span></p>
<dl>
<dt>â€¢</dt>
<dd>reduce the amount of HIV-1 in your blood. This is called â€œviral loadâ€?.</dd>
<dt>â€¢</dt>
<dd>increase the number of CD4+ (T) cells in your blood, which help fight off other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
</dl>
<p>Reducing the amount of HIV-1 and increasing the CD4+ (T) cells in your blood may help improve your immune system. This may reduce your risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or getting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).</p>
<p><span class="Bold">TRIUMEQ does not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or AIDS. </span>You must keep taking HIVâ€‘1 medicines to control HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and decrease HIV-related illnesses.</p>
<p><span class="Bold">Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others. </span></p>
<dl>
<dt>â€¢</dt>
<dd>Do not share or re-use needles or other injection equipment.</dd>
<dt>â€¢</dt>
<dd>Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</dd>
<dt>â€¢</dt>
<dd>Do not have any kind of sex without protection. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions, or blood.</dd>
</dl>
<p>Ask your healthcare provider if you have any questions about how to prevent passing HIV to other people.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">Who should not take TRIUMEQ?</span></p>
<p><span class="Bold">Do not take TRIUMEQ if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have a certain type of gene variation called the HLAâ€‘B*5701 allele. Your healthcare provider will test you for this before prescribing treatment with TRIUMEQ.</dd>
<dt>â€¢</dt>
<dd>are allergic to abacavir, dolutegravir, or any of the ingredients in TRIUMEQ. See the end of this Medication Guide for a complete list of ingredients in TRIUMEQ.</dd>
<dt>â€¢</dt>
<dd>take dofetilide (TIKOSYN<span class="Sup">Â®</span>). Taking TRIUMEQ and dofetilide (TIKOSYN) can cause side effects that may be life-threatening.</dd>
<dt>â€¢</dt>
<dd>have liver problems.</dd>
</dl>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">What should I tell my healthcare provider before taking TRIUMEQ?</span></p>
<p><span class="Bold">Before you take TRIUMEQ, tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have been tested and know whether or not you have a particular gene variation called HLAâ€‘B*5701.</dd>
<dt>â€¢</dt>
<dd>have or have had liver problems, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
<dt>â€¢</dt>
<dd>have kidney problems.</dd>
<dt>â€¢</dt>
<dd>have heart problems, smoke, or have diseases that increase your risk of heart disease such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</dd>
<dt>â€¢</dt>
<dd>drink alcohol or take medicines that contain alcohol.</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. It is not known if TRIUMEQ will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Pregnancy Registry.</span> There is a pregnancy registry for women who take antiretroviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed.<span class="Bold"> Do not breastfeed if you take TRIUMEQ.</span><dl>
<dt>â€¢</dt>
<dd>You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements. </p>
<p>Some medicines interact with TRIUMEQ. <span class="Bold">Keep a list of your medicines to show your healthcare provider and pharmacist. </span>You can ask your healthcare provider or pharmacist for a list of medicines that interact with TRIUMEQ. <span class="Bold">Do not start taking a new medicine without telling your healthcare provider.</span> Your healthcare provider can tell you if it is safe to take TRIUMEQ with other medicines.</p>
<p><span class="Bold">You should not take TRIUMEQ if you also take</span>: </p>
<dl>
<dt>â€¢</dt>
<dd>abacavir (EPZICOM, TRIZIVIR, or ZIAGEN) </dd>
<dt>â€¢</dt>
<dd>lamivudine (COMBIVIR<span class="Sup">Â®</span>, DUTREBISâ„¢, EPIVIR<span class="Sup">Â®</span>, EPIVIR-HBV<span class="Sup">Â®</span>, EPZICOM, or TRIZIVIR) </dd>
<dt>â€¢</dt>
<dd>emtricitabine (ATRIPLA<span class="Sup">Â®</span>, COMPLERA<span class="Sup">Â®</span>, EMTRIVA<span class="Sup">Â®</span>,STRIBILD<span class="Sup">Â®</span>, or TRUVADA<span class="Sup">Â®</span>)</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider if you take:</span></p>
<dl>
<dt>â€¢</dt>
<dd>antacids, laxatives, or other medicines that contain aluminum, magnesium, sucralfate (CARAFATE<span class="Sup">Â®</span>), or buffered medicines. TRIUMEQ should be taken at least 2 hours before or 6 hours after you take these medicines.</dd>
<dt>â€¢</dt>
<dd>anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicines:<dl>
<dt>â€¢</dt>
<dd>oxcarbazepine (TRILEPTAL<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>phenytoin (DILANTIN<span class="Sup">Â®</span>, DILANTIN<span class="Sup">Â®</span>-125, PHENYTEK<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>phenobarbital</dd>
<dt>â€¢</dt>
<dd>carbamazepine (CARBATROL<span class="Sup">Â®</span>, EQUETRO<span class="Sup">Â®</span>, TEGRETOL<span class="Sup">Â®</span>, TEGRETOL<span class="Sup">Â®</span>-XR, TERIL<span class="Sup">Â®</span>, EPITOL<span class="Sup">Â®</span>)</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>any other medicine to treat HIV-1</dd>
<dt>â€¢</dt>
<dd>iron or calcium supplements taken by mouth. Supplements containing calcium or iron may be taken at the same time with TRIUMEQ if taken with food. Otherwise, TRIUMEQ should be taken at least 2 hours before or 6 hours after you take these medicines.</dd>
<dt>â€¢</dt>
<dd>medicines used to treat <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, such as interferon or ribavirin</dd>
<dt>â€¢</dt>
<dd>a medicine that contains metformin</dd>
<dt>â€¢</dt>
<dd>methadone</dd>
<dt>â€¢</dt>
<dd>rifampin (RIFATER<span class="Sup">Â®</span>, RIFAMATE<span class="Sup">Â®</span>, RIMACTANE<span class="Sup">Â®</span>, RIFADIN<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>St. Johnâ€™s wort (<span class="Italics">Hypericum perforatum</span>)</dd>
</dl>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">How should I take TRIUMEQ?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Take TRIUMEQ exactly as your healthcare provider tells you.</span></dd>
<dt>â€¢</dt>
<dd>Do not change your dose or stop taking TRIUMEQ without talking with your healthcare provider. If you miss a dose of TRIUMEQ, take it as soon as you remember. Do not take 2 doses at the same time. If you are not sure about your dosing, call your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>Stay under the care of a healthcare provider while taking TRIUMEQ.</dd>
<dt>â€¢</dt>
<dd>TRIUMEQ may be taken with or without food.</dd>
<dt>â€¢</dt>
<dd>Do not run out of TRIUMEQ. The virus in your blood may increase and the virus may become harder to treat. When your supply starts to run low, get more from your healthcare provider or pharmacy.</dd>
<dt>â€¢</dt>
<dd>If you take too much TRIUMEQ, call your healthcare provider or go to the nearest hospital emergency room right away.</dd>
</dl>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">What are the possible side effects of TRIUMEQ?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">TRIUMEQ can cause serious side effects including:</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">See â€œWhat is the most important information I should know about TRIUMEQ?â€?</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in liver tests. </span>People with a history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C virus may have an increased risk of developing new or worsening changes in certain liver tests during treatment with TRIUMEQ. Your healthcare provider may do tests to check your liver function before and during treatment with TRIUMEQ.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in your immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>)</span> can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after you start taking TRIUMEQ.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in body fat</span> can happen in people who take HIVâ€‘1 medicines. These changes may include an increased amount of fat in the upper back and neck (â€œbuffalo humpâ€?), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The exact cause and long-term health effects of these conditions are not known.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>). </span>Some HIV-1 medicines including TRIUMEQ may increase your risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</dd>
</dl>
<p><span class="Bold">The most common side effects of TRIUMEQ include:</span></p>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â trouble sleepingÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€¢Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></p>
<p>Â Â Â Â Â Â Â Â Â â€¢Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of TRIUMEQ. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1â€‘800â€‘FDAâ€‘1088.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">How should I store TRIUMEQ?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store TRIUMEQ at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</dd>
<dt>â€¢</dt>
<dd>Store TRIUMEQ in the original bottle.</dd>
<dt>â€¢</dt>
<dd>Keep the bottle of TRIUMEQ tightly closed and protected from moisture.</dd>
<dt>â€¢</dt>
<dd>The bottle of TRIUMEQ contains a desiccant packet to help keep your medicine dry (protect it from moisture). Keep the desiccant packet in the bottle. Do not remove the desiccant packet.</dd>
</dl>
<p><span class="Bold">Keep TRIUMEQ and all medicines out of the reach of children.</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">General information about the safe and effective use of TRIUMEQ</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRIUMEQ for a condition for which it was not prescribed. Do not give TRIUMEQ to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about TRIUMEQ that is written for health professionals.</p>
<p>For more information go to <span class="Underline"><a href="http://www.EPZICOM.com">www.TRIUMEQ.com</a></span>or call 1-877-844-8872.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">What are the ingredients in TRIUMEQ?</span></p>
<p>Active ingredients: abacavir, dolutegravir, and lamivudine</p>
<p>Inactive ingredients: D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.</p>
<p>Tablet filmâ€‘coating contains: iron oxide black, iron oxide red, macrogol/PEG, polyvinyl alcoholâ€“part hydrolyzed, talc, and titanium oxide.</p>
<p>Â Â Manufactured for:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â by:</p>
<p>Â Â ViiV HealthcareÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GlaxoSmithKline</p>
<p>Â Â Research Triangle Park, NC 27709Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from Shire Pharmaceuticals Group plc, Basingstoke, UK</p>
<p>COMBIVIR, EPIVIR, EPZICOM, TIVICAY, TRIUMEQ, TRIZIVIR, and ZIAGEN are registered trademarks of the ViiV Healthcare group of companies.</p>
<p>EPIVIR-HBV is a registered trademark of the GSK group of companies.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.</p>
<p>Â©2015 the ViiV Healthcare group of companies. All rights reserved.</p>
<p>TRM:3MG</p>
</td></tr>
<tr class="Last">
<td valign="top"><p class="First">This Medication Guide has been approved by the U.S. Food and Drug Administration.</p></td>
<td align="right" valign="top"><p class="First">Revised: 09/2015</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2190b0e0-a4cd-4698-bcd5-426da26833ce"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINICPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 49702-231-13</span></p>
<p><span class="Bold">Triumeq<span class="Sup">Â®</span></span></p>
<p>(abacavir, dolutegravir, and lamivudine)</p>
<p><span class="Bold">600 mg/50 mg/300 mg</span></p>
<p><span class="Bold">TABLETS</span></p>
<p>Each film-coated tablet contains abacavir sulfate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg of dolutegravir, and 300 mg of lamivudine.</p>
<p>Store in original package at controlled room temperature of 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F)(See USP).  Keep bottle tightly closed; protect from moisture.  Do not remove desiccant.</p>
<p><span class="Bold">Do not use if printed safety seal under cap is broken or missing.</span></p>
<p>See prescribing information for dosage information.</p>
<p><span class="Bold">Notice to Authorized Dispenser:</span></p>
<p>Each time TRIUMEQ is dispensed, give the patient a Medication Guide and Warning Card from the carton.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">30 </span>Tablets</p>
<p>Â©2015, the ViiV Healthcare group of companies.</p>
<dl>
<dt>Â </dt>
<dd>10000000135301	Rev. 8/15</dd>
</dl>
<div class="Figure">
<a name="id1765325"></a><img alt="Triumeq 30 count carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2997739a-aa91-42aa-a206-a70e2db7b84f&amp;name=triumeq-spl-graphic-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIUMEQÂ 		
					</strong><br><span class="contentTableReg">abacavir sulfate, dolutegravir sodium, lamivudine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49702-231</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOLUTEGRAVIR SODIUM</strong> (DOLUTEGRAVIR) </td>
<td class="formItem">DOLUTEGRAVIR</td>
<td class="formItem">50Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ABACAVIR SULFATE</strong> (ABACAVIR) </td>
<td class="formItem">ABACAVIR</td>
<td class="formItem">600Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMIVUDINE</strong> (LAMIVUDINE) </td>
<td class="formItem">LAMIVUDINE</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">572;Tri</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49702-231-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">08/22/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205551</td>
<td class="formItem">08/22/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>ViiV Healthcare Company
							(027295585)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b010f51f-cba6-4fa1-9998-6f83456ce3ed</div>
<div>Set id: 2997739a-aa91-42aa-a206-a70e2db7b84f</div>
<div>Version: 4</div>
<div>Effective Time: 20150928</div>
</div>
</div>Â <div class="DistributorName">ViiV Healthcare Company</div></p>
</body></html>
